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ABSTRACT 
 
BINGYING ZHOU: RAS signaling and therapeutic resistance in melanoma 
(Under the direction of Adrienne D. Cox) 
Increasing appreciation of the complexity of RAS signaling in cancer has led to a 
renewed wave of RAS research. I have focused on two key areas: the role of wild-type RAS 
isoforms in RAS-mutant cancers, and mechanisms of resistance to molecularly targeted 
therapies directed against RAS effector pathways. Melanoma, the most aggressive form of skin 
cancer, presents an excellent model to study RAS signaling; ~90% of melanomas have a driver 
mutation in NRAS (26%) or BRAF (63%), thus hyper-activating the canonical RAS-RAF-MEK-
ERK effector signaling pathway. An army of small molecule inhibitors has emerged to target this 
pathway, and several are FDA-approved for melanoma treatment. However, all targeted 
therapies face the challenge of resistance. Most validated mechanisms of resistance to these 
inhibitors involve either reactivation of ERK signaling or other bypass routes that result in cancer 
cell survival. 
In my investigation of resistance mechanisms in BRAF-mutant melanoma. I found that 
CK2α was sufficient to drive resistance to inhibitors of BRAF (BRAFi) and of MEK (MEKi). CK2α 
facilitated rebound of ERK phosphorylation in the presence of BRAFi, and maintained ERK 
phosphorylation upon treatment with MEKi. Surprisingly, by using a kinase-inactive mutant of 
CK2α, I showed that RAF-MEK inhibitor resistance did not rely on CK2α kinase catalytic 
function. That both wild-type and kinase-inactive CK2α bound equally well to the RAF-MEK-
ERK scaffold KSR1 suggested that CK2α increases KSR facilitation of ERK phosphorylation. 
Accordingly, CK2α did not cause resistance to direct inhibition of ERK by the ERK1/2-selective 
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inhibitor SCH772984. These findings support a new mechanism whereby a kinase-independent 
scaffolding function of CK2α promotes resistance to RAF- and MEK-targeted therapies. 
 Another pressing issue is understanding the biological activities of wild-type RAS 
isoforms in RAS-mutant tumors. Most studies have investigated KRAS-mutant cancers, but little 
is known about NRAS-mutant cancers. NRAS-mutant melanomas comprise the second largest 
subgroup of melanoma patients, and no targeted therapy is approved for these patients. 
Exploring the roles of wild-type RAS isoforms in NRAS-mutant melanoma cells, I found that WT 
KRAS is essential for their proliferation and survival. Interestingly, depletion of KRAS resulted in 
a unique cellular morphology and in signaling outcomes distinct from those due to silencing of 
NRAS or HRAS. Moreover, KRAS knockdown stabilized p53 protein, which was accompanied 
by an increase in p53 target genes. Intriguingly, by using reverse phase protein array analysis, I 
found that KRAS knockdown severely impaired phosphorylation of ribosomal protein S6, 
dependent on S6K1 (p70 S6K) activity, but independent of Akt-mTOR, or ERK-p90RSK activity. 
These results may shed light on the potential efficacy of pan-RAS inhibition in NRAS-mutant 
cancers. 
Together, my findings uncover a novel kinase-independent scaffolding function of CK2α 
in promoting resistance to inhibitors of BRAF and MEK in BRAF-mutant melanoma; highlight the 
critical importance of WT KRAS in NRAS-mutant melanoma; and describe the unique role of 
WT KRAS in maintaining phosphorylation of ribosomal protein S6. How CK2α engages in 
scaffolding to maintain ERK signaling, and how KRAS circumvents Akt-mTOR to regulate 
ribosomal protein S6, are issues to be addressed in future studies of RAS signaling. 
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CHAPTER I: INTRODUCTION 
 
RAS is a small GTPase 
RAS (rat sarcoma viral oncogene homolog) genes were initially identified in acute 
transforming retroviruses as genetic sequences responsible for their oncogenic properties 
(Barbacid, 1987). The identification of mutationally activated human RAS genes as potently 
transforming oncogenes in several contemporary studies (Der et al., 1982; Goldfarb et al., 1982; 
Parada et al., 1982; Pulciani et al., 1982; Santos et al., 1982; Shih and Weinberg, 1982) has 
spawned decades of extensive research into RAS structure, biochemistry, biology, and 
pathobiology (Cox and Der, 2010; Malumbres and Barbacid, 2003). 
RAS proteins are the founding members of the Ras superfamily of small guanosine 
triphosphatases (GTPases) that comprises over 150 members, which are divided into five major 
subfamilies, namely Rab, Ras, Arf, Rho, and Ran (Wennerberg et al., 2005). They are a 
conserved class of low molecular weight (~ 21 kDa), monomeric G-proteins that serve as 
molecular switches in coupling extracellular cues to a variety of intracellular signaling events, to 
regulate a plethora of fundamental cellular processes, including differentiation, proliferation, 
survival, adhesion, migration, vesicular trafficking, nuclear-cytoplasmic transport, etc (Cox and 
Der, 2010). Small GTPases cycle between a GTP-bound, active state, and a GDP-bound, 
inactive state. RAS proteins possess low intrinsic GTP hydrolyzing and guanine nucleotide 
exchange activities. In cells, these processes are accelerated by GTPase activating proteins 
(GAPs) and guanine nucleotide exchange factors (GEFs), respectively. In resting cells, RAS is 
predominantly GDP-bound.  Extracellular stimuli, such as growth factor stimulation, activate 
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GEFs, thereby promoting nucleotide (GDP) release from RAS. Due to the ten-fold higher 
intracellular concentrations of GTP than GDP, RAS transiently binds to GTP, after which GAPs 
quickly return RAS to its resting state (Figure 1.1). Structural studies have uncovered two critical 
stretches of RAS that undergo significant conformational changes when RAS cycles between 
GTP- and GDP-bound states. Termed switch I (amino acids 30-38) and switch II (amino acids 
60-76), these regions are also crucial to RAS interaction with its regulators and effectors. 
Oncogenically activating mutations in RAS, predominantly occurring at residues G12, G13, and 
Q61, impair both intrinsic and GAP-mediated GTP hydrolysis, rendering mutant RAS 
constitutively active (Cox et al., 2014). Analysis of the COSMIC (catalogue of somatic mutations 
in cancer) database reveals that somatic mutations in the three RAS genes are the most 
frequent mutations of oncogenes in human cancers (Cox et al., 2014). In the following section, 
the specific mutational profiles of the RAS isoforms will be introduced. 
 
RAS isoforms are structurally similar but functionally distinct 
The human genome harbors three RAS genes (HRAS, KRAS, and NRAS) at entirely 
different chromosomal locations. HRAS, located on chromosome 11, was the first characterized 
isoform, and dominated RAS research in the early years. The underlying assumption was that 
RAS proteins are functionally redundant and thus interchangeable, which turned out to be an 
oversimplification (Malumbres and Barbacid, 2003; Reddy et al., 1982; Tabin et al., 1982; 
Taparowsky et al., 1982). KRAS, residing on chromosome 12, encodes two splice variants, 
KRAS4A and KRAS4B, the latter of which had been regarded the major isoform expressed in 
human cells. A recent study by Tsai et al. showed that KRAS4B can be expressed at 
comparable levels as KRAS4B (Tsai et al., 2015). A third RAS isoform, previously not identified 
in any retrovirus studies, came to light a year after KRAS, and was designated NRAS 
(chromosome 1), because it was discovered in human neuroblastoma-derived DNA (Hall et al., 
1983; Shimizu et al., 1983; Taparowsky et al., 1983). RAS proteins share 82-90% sequence 
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identity, differing only at their C-termini (hypervariable regions), which are critical for their 
respective lipid modifications, and hence for their membrane targeting and subcellular 
localizations (Cox et al., 2014) (Figure 1.2). 
 Although highly similar in structure, the RAS isoforms have been shown to carry out 
overlapping but still very distinct functions (Castellano and Santos, 2011; Newlaczyl et al., 2014). 
Genetic knockout studies in mice suggested that KRAS is the most important isoform during 
development, since Kras-ablated mice die during embryogenesis (Johnson et al., 1997; Koera 
et al., 1997). In contrast, Nras gene function was shown to be dispensable for normal mouse 
development, growth, and fertility (Umanoff et al., 1995), yet was later found to be important for 
antiviral immune response and T-cell function in mice (Perez de Castro et al., 2003). Neither did 
abrogration of Hras result in any developmental defects (Esteban et al., 2001). However, it 
reduced the numbers of papillomas formed compared with wild-type littermates after 20 weeks 
of 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment (Ise et al., 2000). Strikingly, Hras(-/-
)/Nras(-/-) double knockout mice were viable, and displayed normal development, growth, fertility, 
and neuronal development (Esteban et al., 2001). Both wild-type (WT) NRAS and KRAS were 
found to be required for SV40 TAg-induced transformation in mouse embryonic fibroblasts, 
during which they performed unique functions by engaging different signaling pathways 
(Fotiadou et al., 2007). Specifically, wild-type NRAS regulated adhesion through RAF and RhoA, 
whereas KRAS coordinated motility through AKT and Cdc42.  
In addition to the divergence of their physiological roles, there is also a huge body of 
evidence to suggest different oncogenic potentials and signaling preferences of the mutant RAS 
isoforms, which seem highly context-dependent. For example, in Rat-2 and NIH 3T3 
fibroblasts, transformation assays showed that a G12 mutant of HRAS was more transforming 
than the corresponding NRAS or KRAS mutants. By contrast, in the human multipotent 
haematopoietic cell line, TF-1, NRASG12mut exhibited greater biological activity (Maher et al., 
1995). Importantly, these observations were not due to differences in protein expression or 
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stability, suggesting tissue-specific regulatory components as major players in shaping signaling 
outcomes. Another study compared the effects of the effector loop mutation P24G in RAS 
isoforms in the context of the G12V activating mutation. As expected, P24G diminished both 
RAF-MEK-ERK and PI3K-AKT pathway activity. However, whereas HRASG12V/P34G retained its 
ability to induce transformation of NIH 3T3 cells and to activate RalGDS-RalA and Rac signaling, 
both NRASG12V/P34G and KRASG12V/P34G did not (Oliva et al., 2004). A comparison of 
leukemogenic potentials between NRASG12D, KRASG12D and HRASG12V in a bone marrow 
transplantation mouse model revealed different strengths and distinct phenotypes induced by 
different RAS mutants (Parikh et al., 2007). It was suggested that differential PI3K-AKT pathway 
activation underlies the phenotypic differences among the RAS isoforms. In mice conditionally 
expressing G12D mutants of KRAS or NRAS, KRASG12D led to hyperproliferation of the colon 
epithelium in a MEK-dependent manner. In comparison, NRASG12D did not affect growth of the 
epithelium, but conferred resistance to dextran sodium sulfate (DSS)-induced apoptosis (Haigis 
et al., 2008). Further analysis showed that NRAS formed a signaling complex with RAF-1 and 
STAT3, which activates STAT3 signaling independent of ERK activity (Wang et al., 2013c). In 
immortalized, non-transformed Ink4a/Arf deficient melanocytes, NRASG12V exhibited superior 
tumorigenicity compared to KRASG12V, which was attributed to AKT activation that prevents 
GSK-3-mediated phosphorylation of Myc at T58 (Whitwam et al., 2007), a site commonly 
associated with proteasomal degradation of Myc protein. A retrospective analysis to assess the 
efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal 
cancer in >1,000 human tumor DNA samples concluded that, while KRASmut has a negative 
effect on outcome, NRAS mutations are significantly associated with a low response rate (De 
Roock et al., 2010). 
Another piece of compelling evidence that the three RAS genes are unique is the biased 
frequency and distributions of RAS mutations in human cancers. Analysis of the current 
COSMIC database (http://cancer.sanger.ac.uk/cosmic) (Cox et al., 2014) revealed that HRAS, 
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the isoform that had attracted most attention in the early RAS years, is in fact the least 
frequently mutated isoform (3%) in human cancers. KRAS, on the contrary, is the most 
commonly mutated isoform (86%), and is almost the exclusive isoform mutated in some of the 
most deadliest cancers, such as pancreatic ductal adenocarcinoma and lung adenocarcinoma. 
NRAS is the second most frequently mutated isoform in human cancer (11%), and has been, for 
both historical reasons and its low occurrence in the most dreaded cancers, the “neglected” 
isoform in most RAS studies to date. In addition to the overall mutation frequencies of RAS 
isoforms, there are two other mutational biases. One is the preferential mutation of a specific 
isoform in a given disease. For example, although rare in all cancers, HRAS is the 
predominantly mutated isoform in bladder cancer (57%) and in head and neck squamous cell 
carcinoma (86%). NRAS, which is rarely found in pancreatic ductal adenocarcinoma or lung 
adenocarcinoma, is the major oncogenic isoform in cutaneous melanoma (94%) and acute 
myeloid leukemia (59%). The other bias is a codon-specific mutation signature. As alluded to 
earlier, most RAS mutations (98%) occur at codons G12, G13, or Q61. While 83% of KRAS 
mutations occur at G12, 62% of NRAS mutations occur at Q61. Yet in cutaneous melanoma, 
Q61 mutations account for 87.5% of all NRAS mutant cases (Burd et al., 2014). These 
observations are strong evidence for distinct functionalities of RAS isoforms. 
 
The roles of wild-type RAS in RAS-mutant cancers remain controversial 
While the major focus of RAS research is still on oncogenic RAS, emerging studies are 
casting more emphasis on the interplay between oncogenic and wild-RAS isoforms in tumor 
development and maintenance. In general, wild-type RAS studies are divided into two 
categories: 1) studies of the wild-type counterpart of the oncogenic RAS isoforms, and 2) 
studies of the remaining two wild-type RAS isoforms in the presence of the oncogenic isoform. 
The latter will be a focus of this dissertation. 
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Studies of the functions of wild-type RAS began not long after the characterizations of 
oncogenic RAS. Those early studies primarily focused on the wild-type counterpart of the 
mutant isoform, and most concluded tumor-suppressive roles for wild-type RAS. For example, 
Spandidos and colleagues reported that transfection of the normal human H-ras1 (HRAS) gene 
suppressed the transformed morphology and tumorigenic phenotypes of rat 208F fibroblast 
transformed with the human T24 H-ras1 (HRAS) oncogene. Under these circumstances, the 
expression level of the normal HRAS gene predominated. In rare instances, where transformed 
fibroblasts escaped suppression by normal HRAS, and eventually formed tumors in nude mice, 
expression of normal HRAS was markedly reduced. These findings suggest that HRAS can act 
as a tumor suppressor in mutant-HRAS transformed cells (Spandidos and Wilkie, 1988; 
Spandidos et al., 1990). Likewise, wild-type Kras2, the murine KRAS gene, has been shown to 
suppress the formation of chemically induced lung tumors that harbored Kras2 (Zhang et al., 
2001). Of note, this study utilized a Kras2+/- mouse model that has a heterozygous loss of wild-
type KRAS, which was compared to wild-type mice in all readouts. A similar conclusion was 
drawn for NRAS, which, however, was not studied in the presence of oncogenic NRAS. Instead, 
the study used a carcinogen-induced thymic lymphoma mouse model, and found tumor-
suppressive effects of wild-type NRAS both in the presence of mutant KRAS, and in the 
absence of any mutant RAS (Diaz et al., 2002). More recently, Balmain and colleagues also 
reported tumor suppressive functions of HRASWT and KRASWT in experimental models of 
HRAS-driven non-melanoma skin cancer and KRAS-driven lung cancer, respectively (To et al., 
2013). Interestingly, wild-type Kras4A was identified as the main mediator of both the oncogenic 
activity of mutant KRAS and the suppressor activity of wild-type Kras (To et al., 2008). An 
interesting role of wild-type Kras gene dosage was uncovered in selecting the specific mutation 
induced by urethane. Specifically, wild-type mice carried mostly (94%) Q61R Kras mutations, 
while those from Kras heterozygous animals carried mostly (92%) Q61L mutations (Westcott et 
al., 2015). 
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Loss of the wild-type RAS allele in RAS-mutant cancers is frequently observed, and 
suggests a tumor suppressor role of the wild-type counterpart of oncogenic RAS. When using 
the Kras2LSLMx1-Cre (KM) mouse model to study KrasG12D-induced leukemia, Bergo and co-
workers found that all T-cell acute lymphoblastic leukemia (T-ALL) tumors in bone marrow-
transplanted mice showed loss of the wild-type Kras2 allele, indicating a tumor suppressive role 
of wild-type Kras (Staffas et al., 2015). Zhang et al. showed that, in a fraction of endogenous 
oncogenic KRAS-induced hematopoietic malignancies including acute T-cell lymphoblastic 
leulemia/lymphoma (T-ALL) and myeloproliferative neoplasm (MPN), wild-type Kras expression 
is lost by epigenetic or genetic mechanisms (Kong et al., 2016). Loss of endogenous wild-type 
Hras has also been found at high frequencies in carcinogen-induced skin tumors (Bremner and 
Balmain, 1990). Thymic lymphomas have also been demonstrated to lack the normal allele of 
Nras in carcinogen-induced mouse models (Guerrero et al., 1985).  
 However, there are also studies that have demonstrated tumor-promoting roles of wild-
type RAS (Diaz et al., 2004; Maruyama et al., 2001; Matallanas et al., 2011; Tsunematsu et al., 
1994). By comparing signaling events in an isogenic colorectal cancer cell line pair HCT-116 
(KRASG13D/WT) and Hke3 (KRAS-/WT) with or without selective siRNA-based silencing selectively 
targeting KRASWT, Matallanas et al. demonstrated that KRASG13D activates the proapoptotic 
MST2 pathway. whereas KRASWT antagonizes this activation (Matallanas et al., 2011).  This 
indicates that, in these colorectal cancer cells, wild-type KRAS supports mutant KRAS-induced 
transformation. Collectively, while the vast majority of studies demonstrate an oncosuppressive 
role of the wild-type RAS allele in tumors driven by oncogenic activation of the same RAS 
isoform, it is also true that tissue and/or cellular specificity can influence the role that wild-type 
RAS plays in tumors. 
Most of the other subset of RAS studies that focused on wild-type RAS isoforms other 
than the oncogenically mutated isoform have, in contrast, revealed tumor-promoting functions.  
For example, in a study aimed at understanding the mechanism of FTI (farnesyl transferase 
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inhibitor)-mediated radiosensitization in cell lines that express oncogenic KRAS, the authors 
found that wild-type HRAS, although not wild-type NRAS, contributes to radiation survival in 
most pancreatic and colorectal carcinoma cell lines tested (Cengel et al., 2007).  Similarly, 
Panayotou et al. reported that ectopic expression of KRASG12V in the Caco-2 colorectal cancer 
cell line increased expression and activity of endogenous HRAS, and that oncogenic KRAS 
partly exerted its effects, such as enhanced invasiveness, through wild-type HRAS (Ikonomou 
et al., 2012). Likewise, Keller and co-workers demonstrated that the presence of 
an oncogenic KRAS allele resulted in elevated levels of GTP-bound NRAS in two human 
colorectal cancer cell lines, HCT 116 and DLD-1, compared to their isogenic counterparts in 
which the mutant KRAS allele was disrupted by homologous recombination (Keller et al., 2007). 
Detailed mechanistic insight was first provided by Lim et al., who showed that activation of 
eNOS (endothelial nitric oxide synthase) by phosphorylation of S1177 promotes C118 S-
nitrosylation and activation of endogenous wild-type RAS proteins, suggesting that an 
oncogenic RASmut-PI3K-AKT-eNOS-RASWT pathway is required for tumor initiation and 
maintenance (Lim et al., 2008). They pointed out in particular that the activation of the other 
wild-type RAS family members by eNOS may serve as an important means to diversify RAS 
signaling beyond that of oncogenic RAS. In agreement with their speculation, they found that 
loss of wild-type HRAS does not inhibit oncogenic HRASG12V-mediated oncogenesis in TtH cells 
expressing either scramble or HRAS shRNA in addition to RNAi-resistant oncogenic HRASG12V. 
In fact, the wild-type counterparts of the oncogenic RAS proteins are often deleted in cancers (Li 
et al., 2003; Wan et al., 2006), suggesting that, in contrast to the non-counterpart wild-type 
isoforms, these play a tumor-suppressive role. 
It seems that the interaction between oncogenic and wild-type RAS proteins is the net 
result of a multitude of diverse mechanisms, as the following studies have presented ways of 
crosstalk. Oncogenic KRAS has been demonstrated to promote allosteric stimulation of SOS, a 
well-known RAS GEF, and leads to activation of wild-type HRAS and NRAS (Jeng et al., 2012). 
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A later study by the same group provided additional insights into RAS protein interactions 
(Grabocka et al., 2014), where wild-type HRAS or NRAS depletion in mutant KRAS cancer cells 
resulted in hyperactivation of both ERK-p90 RSK and PI3K-AKT pathways, thereby 
phosphorylating Chk1 at an inhibitory site, S280. Consequently, the G2 DNA damage 
checkpoint was inhibited, leading to increased sensitivity of KRAS-mutant cells to DNA 
damaging agents, such as irinotecan, a topoisomerase I inhibitor that is FDA-approved for the 
treatment of colorectal cancer. Furthermore, oncogenic and wild-type RAS isoforms have been 
reported to be responsible for regulating different aspects of signal transduction, with oncogenic 
RAS modulating basal mitogen-activated protein kinase (MAPK) pathway signaling, and wild-
type isoforms controlling response to growth factor signaling (Young et al., 2013). However, 
surprisingly little is known about whether NRAS-mutant cancers require KRASWT or HRASWT for 
tumor initiation and/or maintenance. It is therefore an aim of my thesis work to understand the 
roles of wild-type RAS isoforms in a NRAS mutant setting. 
 
RAS effector pathway signaling is frequently deregulated in cancer 
There are at least 11 identified direct effectors of RAS, including RAF, PI3K, RalGDS, 
Tiam1, PLCε, etc. (Figure 1.3). Among all downstream pathways, the RAF-MEK-ERK and the 
PI3K-AKT-mTOR pathway are by far the best studied. The RAF-MEK-ERK pathway, the first 
RAS effector pathway delineated, has been shown in various contexts to contribute significantly 
to tumor development (Blasco et al., 2011; Collisson et al., 2012; De Luca et al., 2012; 
Khosravi-Far et al., 1995; Stang et al., 1997), and thus has been a major focus of targeted 
therapies (Roberts and Der, 2007; Samatar and Poulikakos, 2014; Santarpia et al., 2012). A 
detailed discussion of this crucial pathway is provided in the following section. 
The PI3K-AKT-mTOR pathway is the second-best studied pathway identified 
downstream of RAS (Cantley, 2002), and is involved in many cellular processes relevant to 
cancer, including metabolism, inflammation, cell survival, motility, and overall cancer 
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progression (Vanhaesebroeck et al., 2010). In 1994, the p110 catalytic subunits of class I PI3K 
(phosphatidylinositol-4,5-bisphosphate 3-kinase) were identified as direct downstream targets of 
RAS  (Kodaki et al., 1994; Rodriguez-Viciana et al., 1994). PI3K is a lipid kinase that 
phosphorylates the 3’-hydroxyl group of PIP2 (phosphatidylinositol-4,5-bisphosphate), 
converting the latter into PIP3 (phosphatidylinositol-3,4,5-trisphosphate), which then recruits 
AKT to the plasma membrane to further transmit signaling. On the other hand, PIP3 is negatively 
regulated by dephosphorylation by the tumor suppressor, PTEN (phosphatase and tensin 
homolog). Upon translocation to the plasma membrane, AKT can be phosphorylated by PDK1 
on its activation loop (T308) (Wick et al., 2000), which is sufficient to activate the mammalian 
target of rapamycin complex 1 (mTORC1) by direct phosphorylation on Ser2448 (Nave et al., 
1999).  Activation of mTORC1 results in increased protein synthesis and cell survival upon 
phosphorylation of two key effectors. Phosphorylation of 4E-BPs (elF4E-binding proteins) 
terminates their binding to elF4E and relieves the block on translation initiation (Aoki et al., 
2001; Nave et al., 1999), whereas phosphorylation of p70 ribosomal S6 kinases (S6K1 and 
S6K2) (Dufner and Thomas, 1999; Saitoh et al., 2002) activates their major target, ribosomal 
protein S6 (rpS6). While mTORC1 signals downstream of PI3K-AKT, another mTOR complex, 
mTORC2, contributes to the full activation of AKT by phosphorylating it on Ser473 (Zhang et al., 
2012) (Figure 1.4). PI3K-AKT-mTOR signaling has long been known to be deregulated in 
cancer (Sheridan and Downward, 2013; Yuan and Cantley, 2008), which can occur either 
through upstream activation by oncogenic RAS, or through genetic alterations of pathway-
specific components, such as mutations in p110α (Gustin et al., 2008; Ligresti et al., 2009; 
Samuels and Waldman, 2010; Samuels et al., 2004), inactivation of PTEN (Li et al., 1997; 
Parsons, 2004; Steck et al., 1997), and amplifications in AKT (Cheng et al., 1992; Cheng et al., 
1996; Staal, 1987), etc. Notably, many tumors depend on pathway signaling for tumor initiation 
and/or maintenance (Castellano et al., 2013; Gupta et al., 2007; Lim et al., 2008; Lim and 
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Counter, 2005), resulting in epic efforts to develop small molecule inhibitors against components 
of this pathway. To date, at least 53 inhibitors of PI3K-AKT-mTOR inhibitors have reached 
clinical evaluation (Cox et al., 2014). While showing minimal promise as monotherapeutics, they 
potentially yield powerful synergism when combined with inhibitors of the RAF-MEK-ERK 
pathway (Engelman et al., 2008; Ewald et al., 2014; Jin et al., 2011; Lasithiotakis et al., 2008; 
Meier et al., 2007; Pitts et al., 2014). 
Another major RAS downstream effector pathway is the RalGEF-RalA/RalB axis. RalA 
and RalB are two highly related (82% overall amino acid sequence identity) small GTPases of 
the RAS subfamily (Gentry et al., 2014). The importance of Ral activity has been established in 
many human cancers, including non-small cell lung cancer (NSCLC), melanoma, ovarian 
cancer, colorectal cancer, bladder cancer, pancreatic cancer, etc. (Coltart et al., 1990; Guin and 
Theodorescu, 2015; Lim et al., 2006; Mishra et al., 2010; Smith et al., 2007; Wang et al., 2010; 
Wang et al., 2013a; Zipfel et al., 2010). In contrast to the RAF-MEK-ERK pathway or the PI3K-
AKT-mTOR pathway, Ral downstream signaling is less well characterized, and components of 
this pathway are not mutated in cancer. The first effector identified for Ral was RalBP1 (Cantor 
et al., 1995; Jullien-Flores et al., 1995; Park and Weinberg, 1995), which is also the most 
studied. Xenograft studies have demonstrated that RalBP1 plays an important role in several 
tumor types, such as pancreatic (Leake et al., 2012), prostate (Wu et al., 2010), colorectal 
(Mollberg et al., 2012), bladder (Wu et al., 2010), and glioblastoma (Wang et al., 2013b). Other 
well-established effectors of Ral include Sec5 and Exo84 (Moskalenko et al., 2002), which are 
subunits of the octomeric exocyst complex, and have been implicated in fostering oncogenic 
RAS-mediated tumorigenesis (Issaq et al., 2010). 
Although the aforementioned pathways remain the top three most influential RAS 
effector pathways studied to date, significant contributions of other pathways to RAS-mediated 
oncogenesis cannot be excluded, owing to a lesser understanding of them. Indeed, some of 
these pathways have started to emerge as important players in cancer, such as Tiam1-RAC-
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PAK signaling (Baker et al., 2014; Dummler et al., 2009), RASSF-Mst1/2 signaling (Chao et al., 
2015; Maruyama et al., 2008; Mezzanotte et al., 2014; Zhou et al., 2014), and PLCε-PKC 
signaling (Dowling et al., 2016; Leonard et al., 2015; Martins et al., 2014). 
 
The RAS-RAF-MEK-ERK “pathway” is really a “web” 
The RAS-RAF-MEK-ERK cascade is without doubt one of the best-characterized signal 
transduction pathways in science history. The initial illustration of this pathway as a linear and 
unidirectional flow was later extensively revised based on studies that continued to add 
complexities to it, rendering the pathway now the core of a complex signaling network (Figure 
1.5). In 1993, four groups reported the direct interaction of the RAF serine/threonine kinase 
(specifically RAF-1 or CRAF) with RAS, making it the first bona fide mammalian RAS effector to 
be identified (Moodie et al., 1993; Vojtek et al., 1993; Warne et al., 1993; Zhang et al., 1993). In 
fact, the human RAF family comprises three evolutionarily conserved cytosolic RAF kinases, 
ARAF, BRAF and CRAF (Desideri et al., 2015). When GTP-bound, whether through growth 
factor stimulation or mutation, the affinity of RAS towards RAF increases due to conformational 
change, leading to RAS-RAF binding via the RAS-binding domain (RBD) (Nassar et al., 1995; 
Vojtek et al., 1993) and the cysteine-rich domain (CRD) (Mott et al., 1996) on RAF (Roskoski, 
2010). This physical interaction tethers cytoplasmic RAF to the plasma membrane, and is 
considered the first step in its activation (Morrison and Cutler, 1997). Once bound to RAS, the 
conformation of RAF changes, rendering it accessible for additional modifications, such as 
phosphorylation at Y340/341 by Src family kinases, which had been shown to enhance the 
catalytic activity of RAF (Fabian et al., 1993; Marais et al., 1995). In addition, oligomerization, 
which can be induced by the enrichment of RAF at the plasma membrane when bound to RAS, 
is also a means of RAF activation (Farrar et al., 1996; Luo et al., 1996). Indeed, it is well 
established that RAF dimerization is necessary for its kinase activity (Rajakulendran et al., 
2009; Rushworth et al., 2006). Upon full activation of RAF, it can further transmit the signal by 
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phosphorylating and activating MEK (or MKK, mitogen-activated protein kinase kinase). Two 
highly-related MEK1 and MEK2 proteins share 80% sequence identity, and are the only well-
validated RAF substrates. Activated MEK then propagates the signal to its downstream 
effectors ERK1 and ERK 2 (extracellular signal-regulated kinase), which have 86% sequence 
identity, and are the only well-validated MEK substrates. ERK1/2, however, has over 200 
substrates, distributed throughout the cell (Roskoski, 2012). The most thoroughly studied 
nuclear substrate of ERK1/2 is Elk1 (Yoon and Seger, 2006), a member of the ternary complex 
factor subfamily of Ets (E-twenty six)-domain transcription factors, which play a major role in 
inducing the expression of immediate early genes. The best-known cytoplasmic substrates of 
ERK1/2 are p90 RSK family kinases, which are known to regulate cell growth, motility, and 
survival (Anjum and Blenis, 2008).  
In addition to forward propagation of signal, the pathway is also regulated by feedback 
phosphorylation to restrict signaling output and provide a sensitive and temporal modulation of 
RAS-RAF-MEK-ERK signaling. Morrison and colleagues reported that a series of ERK-
catalyzed phosphorylation sites (Ser151, Thr401, Ser750, and Thr753) are associated with 
feedback inhibition of BRAF (Ritt et al., 2010). Specifically, phosphorylation of these sites 
inhibits BRAF binding to activated RAS and disrupts heterodimerization with CRAF, whereas 
mutation of each feedback site increased transformation and correlated with 
enhanced heterodimerization and activation of CRAF. Similarly, ERK1/2 phosphorylation of HA-
BRAF at Thr753 exerts negative feedback on the persistence of the HA-BRAF/FLAG-CRAF 
heterodimer and decreases BRAF kinase activity (Rushworth et al., 2006). The phosphorylation 
of six serine residues (29, 43, 289, 296, 301, and 642) on CRAF/RAF-1 has been reported to be 
catalyzed by ERK1/2, hyperphosphorylation of which inhibited RAS-CRAF interaction and 
desensitized RAF to additional stimuli (Dougherty et al., 2005). Moreover, ERK1/2 also 
catalyzes inhibitory feedback phosphorylation of MEK1 on Thr292 (Brunet et al., 1994; 
Catalanotti et al., 2009) and Thr398 (Brunet et al., 1994; Matsuda et al., 1993). Catalanotti et al. 
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showed that the MEK1/MEK2 heterodimer is negatively regulated by ERK-mediated 
phosphorylation of MEK1 on Thr292, a residue not present in the proline-rich sequence of 
MEK2 (Catalanotti et al., 2009). This phosphorylation blocks the ability of PAK to phosphorylate 
S298 and of Rac-PAK signaling to enhance MEK1-ERK complex formation (Eblen et al., 2004). 
The mechanism by which the other phosphorylation site, Thr398, attenuates MEK-ERK 
signaling, however, is less well understood. ERK, and its immediate substrate p90 RSK-2, are 
both capable of phosphorylating son of sevenless 1 (SOS1) at several residues, thereby 
interfering with SOS1 binding to Grb2, an adaptor protein that couples RTKs to RAS, leading to 
the ultimate downregulation of RAS signaling (Corbalan-Garcia et al., 1996; Douville and 
Downward, 1997). Further downstream, activation of ERK1/2 signaling induces the 
transcriptional upregulation of some negative regulators of the pathway, including dual-
specificity MAP kinase (MAPK) phosphatases (MKPs or DUSPs) and Sprouty (SPRY) proteins. 
ERK1/2 signaling drives the expression of a variety of DUSP proteins, including the ERK-
specific phosphatases DUSP5 (nuclear) and DUSP6/MKP3 (cytoplasmic) (Kidger and Keyse, 
2016; Zhang et al., 2010), thus providing a straightforward means of controlling its own activity. 
The importance of DUSPs in controlling RAF-MEK-ERK signaling is exemplified by the frequent 
loss of DUSP6 in EGFR- and KRAS-driven non-small cell lung cancers (Zhang et al., 2010) and 
by the demonstration that the loss of DUSP5 accelerates HRAS-driven skin cancer in mice 
(Rushworth et al., 2014). 
SPRY proteins have also been identified to act as negative regulators of RTK-RAS-RAF-
MEK-ERK signaling (Hanafusa et al., 2002; Kim and Bar-Sagi, 2004). Growth factor stimulation 
leads to the tyrosine phosphorylation and plasma membrane translocation of SPRY1 and 
SPRY2, where they bind the adaptor protein Grb2 to prevent recruitment of the Grb2-SOS 
complex either to the fibroblast growth factor receptor (FGFR) docking adaptor protein FRS2 or 
to SH2-domain-containing protein tyrosine phosphatase-2 (SHP2), thereby blocking the 
necessary step in coupling FGFR stimulation to RAS activation (Hanafusa et al., 2002). 
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Understanding such negative feedback regulation is important for predicting the consequences 
of pharmacologically inhibiting elements of this pathway for cancer treatment, as well as for 
unraveling the consequences of signaling from wild-type RAS isoforms in the presence of 
oncogenic RAS. 
Scaffolding proteins, such as kinase suppressor of RAS (KSR), also play an important 
role in shaping RAS-RAF-MEK-ERK signaling (Kolch, 2005). A variety of scaffold proteins 
including KSR1/2, IQGAP1, MP1, β-Arrestin1/2 participate in regulation of the RAF-MEK-ERK 
kinase cascade (Morrison and Davis, 2003). The human genome encodes two KSRs, KSR1 
and KSR2. Sequence analysis indicates that KSR1/2 belong to the protein-serine/threonine 
kinase family. These proteins were considered catalytically inactive owing to the absence of 
critical conserved amino acid residues. Emerging studies have shown otherwise, but the bulk of 
evidence still supports a kinase-independent function of KSR. KSR1 binds all modules of the 
RAF-MEK-ERK pathway, but, whereas MEK is associated constitutively, RAF and ERK might 
bind in a stimulus-dependent manner (Morrison, 2001). KSR1-/- mice were found to be less 
susceptible to oncogene-induced tumors than their wild-type counterparts (Kortum and Lewis, 
2004; Lozano et al., 2003; Nguyen et al., 2002), supporting a role for KSR1 in promoting the 
proliferative and transforming functions of the RAF-MEK-ERK pathway. As discussed in Chapter 
2, I have found a previously unrecognized role for a KSR-interacting protein in modulating 
responses to pharmacological inhibition of the RAF-MEK-ERK kinase cascade. 
Finally, there is extensive crosstalk among the different RAS effector pathways. For 
example, there are multiple levels of crosstalk among the RAF-MEK-ERK, PI3K-AKT-mTOR, 
and RAC-PAK pathways (Aksamitiene et al., 2012; Ebi et al., 2013; Eblen et al., 2002; Wang et 
al., 2013d). Of note, cross-talk is context-dependent and pathways can activate or inhibit each 
other. 
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CK2 modulates RAF-MEK-ERK pathway activity and vice versa 
Amongst all the molecules that can modulate RAF-MEK-ERK activity, protein kinase 
CK2 is not one that is commonly thought of. However, there have been multiple reports of CK2 
affecting the signaling output of the RAF-MEK-ERK pathway. Protein kinase CK2, formerly 
known as “casein kinase 2”, is a widely expressed, constitutively active kinase that 
phosphorylates nearly 300 protein substrates, and plays important roles in cellular survival, 
proliferation and differentiation (Pinna, 2002; Pinna and Allende, 2009; Trembley et al., 2009). 
The CK2 tetrameric holoenzyme is composed of two regulatory (β) and two catalytic (α or α’) 
subunits. There is substantial evidence to suggest that the subunits can also function 
independently of the tetramer (Hanif et al., 2010). 
The modulatory effect of CK2 on RAF-MEK-ERK signaling can happen at various levels. 
The Goldberg laboratory reported CK2α binding to the core dimer of protein phosphatase 2A 
(PP2A) (Heriche et al., 1997), a phosphatase that is known to be principally responsible for the 
down-regulatory dephosphorylation of kinases belonging to the RAF-MEK-ERK pathway 
(Hunter, 1995). Overexpression of wild type CK2α inhibited serum-stimulated activation of co-
transfected MEK1 and suppressed cell growth. CK2α also dramatically reduced (by 60%) the 
focus forming capability induced by RasG12V, but not by constitutively active MEK1, in NIH 3T3 
cells. These data suggest that CK2α binding to PP2A may enhance PP2A activity toward 
MEK1. Later, the same group showed that CK2α could also inhibit serum-stimulated activation 
of ERK2, and that expression of activated viral Raf disrupted CK2α-PP2A association (Lebrin et 
al., 1999). While these studies identified a negative regulatory role of CK2α on the RAF-MEK-
ERK kinase cascade, others found positive roles. For example, CK2α has also been shown to 
interact with and phosphorylate the ERK-specific dual specificity phosphatase 6 (DUSP6), also 
known as MAP kinase phosphatase 3 (MKP3). This resulted in a slight increase in EGF-
stimulated ERK phosphorylation in COS-7 cells (Castelli et al., 2004). In vitro studies have 
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demonstrated that, upon EGFR activation, ERK2 directly binds CK2α via the ERK2 docking 
groove and phosphorylates CK2α at Thr360 and Ser362, thereby enhancing CK2α activity 
toward α-catenin phosphorylation (Ji et al., 2009). Furthermore, CK2 has been characterized as 
an integral component of the KSR1 scaffolding complex, and has been shown to be critical to 
the maximal activation of this pathway (Ritt et al., 2007). Aside from fine-tuning the signaling 
amplitude of the RAF-MEK-ERK pathway, CK2 has been reported to regulate ERK nuclear 
translocation and translation of nuclear targets of ERK, which, in essence, can also affect the 
signaling efficiency of the pathway (Plotnikov et al., 2011). Mechanistically, CK2 can 
phosphorylate Ser244 and Ser246 in the nuclear translocation signal (NTS) of ERK, allowing 
ERK binding to Imp7 (importin 7), a protein that is responsible for the nuclear import of many 
proteins.  
Although the interactions between CK2 and the RAF-MEK-ERK pathway are 
sophisticated and relatively poorly defined, the following can be concluded from the above 
studies related to CK2 and RAF-MEK-ERK signaling: 1) CK2 is both a target and a regulator of 
RAF-MEK-ERK signaling, and 2) there are multiple ways by which CK2 and components of the 
RAF-MEK-ERK pathway can interact with and modulate each other's activity. 
 
RAS-RAF-MEK-ERK signaling is critical to RAS- and RAF-driven cancers 
Hyperactivation of the RAS-RAF-MEK-ERK pathway occurs very frequently in solid 
tumors, and is often the result of activating mutations in upstream receptor tyrosine kinases, 
RAS, or BRAF. For example, it is known that EGFR-mutant non-small cell lung cancers 
constitutively express active ERK (Balko et al., 2009; Britson et al., 2009). Activating RAS 
mutations or loss of the RasGAP NF1 can cause activation of the pathway at the level of RAS. 
RAS, especially KRAS, gain-of-function mutations occur at extremely high frequencies in 
pancreatic (Almoguera et al., 1988), colorectal (Cancer Genome Atlas, 2012), lung (Cancer 
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Genome Atlas Research, 2014a), and endometrial adenocarcinomas (Cancer Genome Atlas 
Research et al., 2013), whereas NF1 loss-of-function mutations are more commonly seen in 
melanomas (Cancer Genome Atlas, 2015), glioblastomas (Verhaak et al., 2010), and lung 
squamous cell carcinomas (Cancer Genome Atlas Research, 2014a). The next module in the 
tier, RAF, specifically BRAF, is frequently mutated in melanomas (Cancer Genome Atlas, 2015) 
and in papillary thyroid carcinomas (Cancer Genome Atlas Research, 2014b). In sharp contrast, 
MEK and ERK mutations are very rarely found in human cancers. 
Given the frequency of mutational activation of the pathway and its importance in tumor 
maintenance, it is therefore not surprising that considerable efforts have been made to develop 
targeted therapies against RAS-driven cancers that are directed against the RAF-MEK-ERK 
kinase cascade (Samatar and Poulikakos, 2014). Attempts to target active RAS in the early 
days focused on targeting RAS membrane association, using FTIs to block RAS obligate lipid 
modification by farnesylation. However, despite their preclinical efficacy in tumor models, FTIs 
proved unsuccessful in the clinic for a variety of reasons including their failure to block 
alternative prenylation of KRAS and NRAS (Berndt et al., 2011). The next big step was a leap 
towards designing inhibitors that target RAS downstream signaling, in particular the RAF-MEK-
ERK and PI3K-AKT-mTOR cascades. Here, I will focus on inhibitors of the RAF-MEK-ERK 
pathway. 
Mutant BRAF-specific inhibitors vemurafenib and dabrafenib, which specifically inhibit 
BRAFV600E, the predominant oncogene in melanoma patients, cause >80% inhibition of 
phosphorylated in ERK in tumors, and thus have shown significant clinical efficacy (Bollag et al., 
2010; Chapman et al., 2011; Hauschild et al., 2012). However, using these first-generation 
mutant-specific inhibitors in non-BRAF-mutant settings, such as for RAS-mutant cancers, can 
lead to the paradoxical activation of MEK-ERK signaling resulting from increased BRAF-CRAF 
dimerization. Drug binding to the heterodimer inhibits BRAF, but transactivates CRAF, thereby 
hyperactivating the pathway (Poulikakos et al., 2010). This paradoxical activation of RAS-MEK-
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ERK signaling can be manifested by the appearance of an array of secondary lesions, including 
papillomas, squamous cell carcinomas, keratoacanthomas, and basal cell carcinomas, in those 
parts of the skin without BRAF mutations (Holderfield et al., 2014a; Su et al., 2012). 
A huge number of studies has reported the use of various MEK inhibitors to inhibit tumor 
cell proliferation in culture and to block tumor growth in animal models (Sebolt-Leopold and 
Herrera, 2004), underscoring the wide range of MEK dependency in different tumor systems. 
However, the dependence on MEK appears highest in tumors that harbor a BRAF mutation 
(Solit et al., 2006), perhaps because mutated BRAF transmits signal only through the RAF-
MEK-ERK pathway, whereas mutated RAS, for instance, can utilize several effector pathways. 
Interestingly, structural and functional studies demonstrated that MEK inhibitors with superior 
efficacy in KRAS-mutant cancers, such as GDC-0623 and G-573, form a strong hydrogen bond 
with Ser212 in MEK and thus block MEK feedback phosphorylation by wild-type RAF 
(Hatzivassiliou et al., 2013). In comparison, MEK inhibition in BRAF-mutant cancers requires 
potent inhibition of active, phosphorylated MEK, which is achieved by inhibitors such as GDC-
0973 (cobimetinib). Another study agrees with this finding and revealed that MEK activated by 
CRAF was less susceptible to MEK inhibitors than when activated by BRAFV600E, and that MEK 
inhibitors induced RAF-MEK complexes in KRAS-mutant models, explaining the marginal 
efficacies of MEK inhibitor in RAS-driven cancers (Lito et al., 2014). Therefore, the mechanisms 
by which MEK inhibitors function can determine their efficacies in BRAF- versus KRAS-mutant 
tumors. Generally, MEK inhibitors are classified into ATP-competitive and non-ATP-competitive 
(allosteric) inhibitors, but most MEK inhibitors belong to the latter category. At present, at least 
15 MEK inhibitors have entered clinical evaluation (Cox et al., 2014). Among them, trametinib 
and cobimetinib have been approved by the FDA for use in BRAF-mutant metastatic 
melanomas, whereas selumetinib is approved for treatment of uveal melanoma, a rare eye 
cancer driven largely by mutations in GNAQ and GNA11 rather than in BRAF or RAS. 
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ERK inhibitors are also emerging, prompted by the observation that ERK reactivation is 
a major cause for resistance to RAF or MEK inhibition (Lito et al., 2013). Three ERK inhibitors 
(BVD-523, GDC-0994, MK-8353/SCH-900353) have reached clinical evaluation (Cox et al., 
2014), and SCH772984, an analog of MK-8353, has been well characterized in preclinical 
models (Morris et al., 2013). Whether ERK inhibitors will be superior to RAF or MEK inhibitors 
remains to be determined. 
 
Resistance to targeted therapies remains a major challenge in treating RAS- or RAF-
driven cancers 
 
A common theme of targeted therapies is the emergence of drug resistance, despite 
remarkable initial tumor responses. The study of resistance mechanisms is necessary for 
uncovering new therapeutic targets or rationalizing drug combinations that forestall or delay 
tumor relapse (Zhou and Cox, 2015). Among all classes of inhibitors, the resistance 
mechanisms for BRAF inhibition are best characterized (Hartsough et al., 2014; Lito et al., 2013; 
Spagnolo et al., 2015) (Figure 1.6). Resistance is broadly divided into two not mutually exclusive 
categories: intrinsic and acquired resistance. Approximately 50% of BRAF-mutated melanoma 
patients show no response (~15% of them) or little response (~35% of them), as defined by a 
degree of tumor shrinkage sufficient to meet the RECIST criteria for a partial response to BRAF 
inhibition (intrinsic resistance) (Chapman et al., 2011; Flaherty et al., 2010; Sosman et al., 
2012). The other half of treated patients initially display response to therapy (>30% tumor 
shrinkage), but eventually develop secondary tumors that display acquired resistance to these 
inhibitors. 
Compared to intrinsic resistance, acquired resistance is more clearly defined and 
investigated. Mechanism-wise, acquired resistance largely fits into two subcategories: 
mechanisms that ultimately result in ERK reactivation (major), and mechanisms that reduce the 
dependence of tumors on ERK signaling (minor). Based on the above discussion regarding 
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RAS-RAF-MEK-ERK signaling, it can be predicted that factors that enhance RAF 
dimerization/signaling will eventually reactivate ERK. Accordingly, Nazarian et al. (Nazarian et 
al., 2010) reported that acquired resistance to PLX4032 (vemurafenib) develops by mutually 
exclusive upregulation of PDGFRβ or mutations in NRAS, mechanisms that have also been 
found in patient tumor samples. In one subset, PDGFRβ-upregulated tumor cells have low 
levels of activated RAS, and, when treated with vemurafenib, do not reactivate the MAPK 
pathway significantly. In contrast, in another subset, high levels of activated NRAS resulting 
from NRAS mutations lead to significant MAPK pathway reactivation upon vemurafenib 
treatment. The occurrence of secondary NRAS mutations in previously regressed tumors was 
independently validated in a separate study, where they were found in 4 out of 19 tumor 
progression samples (Poulikakos et al., 2011). Loss of NF1, a RAS GAP and tumor suppressor, 
has also been shown to promote resistance to RAF inhibition by enhancing ERK signaling, and 
has been validated as a potential mechanism of intrinsic resistance in cell culture, as well as of 
acquired resistance in patient tumor samples (Maertens et al., 2013; Whittaker et al., 2013). 
These alterations upstream of RAF can promote signal transmission to wild-type RAF, 
particularly CRAF, the active protomer of the inhibitor-bound BRAF-CRAF heterodimer. At the 
level of RAF, amplifications in BRAF (Shi et al., 2012b) or CRAF (Johannessen et al., 2010; 
Montagut et al., 2008), alternative splicing of mutant BRAF (Poulikakos et al., 2011), as well as 
increased expression of an alternative MAPKKK, COT (also known as Tpl-2) (Johannessen et 
al., 2010), have been documented as resistance mechanisms. A 61 kDa alternatively spliced 
form of BRAFV600E lacking exons 4-8 (encoding the RAS binding domain of BRAF) has been 
reported to dimerize independently of RAS, thus conferring resistance to vemurafenib, 
consistent with the model that only BRAFV600E monomers are sensitive to inhibition. Importantly, 
this splice variant has been identified in both resistant cell lines generated in vitro and 
vemurafenib-resistant patient tissue. Downstream of RAF, mutations such as C121S (Wagle et 
al., 2011), P124L (Emery et al., 2009) and Q56P (Emery et al., 2009) in MAP2K1, which 
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encodes MEK1, have also been shown to confer RAF inhibitor resistance. However, the 
significance of other MEK mutations needs further interrogation, because although P124S and 
I111S mutations in MEK1 have been detected in pre-treatment samples, they do not provide 
resistance to RAF inhibitors (Shi et al., 2012a).  
Mechanisms of acquired resistance that attenuate the dependence of tumor cells on 
ERK usually involve the activation of other parallel pathways that bypass the need for ERK 
signaling. For example, increased AKT pathway signaling, resulting from the concurrent loss of 
the PTEN and RB1 tumor suppressors, is capable of diminishing RAF-MEK-ERK dependence in 
BRAF-mutant melanomas (Xing et al., 2012). Upregulation of RTK signaling is another means 
by which tumor cells become less dependent on ERK signaling. Using a panel of kinase-
'addicted' human cancer cell lines, Settleman and co-workers found that most cells can be 
rescued from drug sensitivity by simply exposing them to one or more RTK ligands (Wilson et 
al., 2012). Girotti et al. demonstrated that BRAF inhibitor-mediated activation of EGFR-SFK (Src 
family kinase)-STAT3 signaling mediated drug resistance in patients with BRAF-mutant 
melanoma (Girotti et al., 2013). Villanueva, Herlyn and colleagues reported an IGF-1R/PI3K-
dependent survival mechanism in the development of resistance to BRAF inhibitors (Villanueva 
et al., 2010). 
Resistance mechanisms to MEK-targeted agents (Caunt et al., 2015; Poulikakos and 
Solit, 2011; Sale and Cook, 2014) are often distinct from those to RAF-targeted therapies and 
have largely been characterized preclinically in colon cancer cell lines. In sharp contrast to RAF 
inhibition, where no secondary BRAF gatekeeper mutation has been identified (Whittaker et al., 
2010), resistance to MEK inhibition can arise through mutations in MEK. For example, 
MEK1V211D and MEK1G128D/L215P mutations were identified in RKO (BRAFV600E) cells and in HCT-
116 (KRASG13D) colon cancer cells, respectively, that displayed acquired resistance to the 
MEK1/2 inhibitor trametinib (Morris et al., 2013). Likewise, a MEK1F129L mutation was found in 
HT-29 (BRAF-mutant, KRAS-WT) colon cancer cells as a molecular mechanism responsible for 
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resistance to MEK inhibitor RO4927350 (Wang et al., 2011). The clinical relevance of MEK1 
mutations as a mechanism of acquired resistance to MEK1/2 inhibitors was highlighted by the 
identification of a MEK1P124L mutation in a metastastic focus of a patient post-selumetinib 
relapse that was undetectable in pre-treatment samples (Emery et al., 2009). Additionally, 
concurrent MEK2Q60P mutation and BRAFV600E amplification was found to promote resistance to 
trametinib (Villanueva et al., 2013). Another type of MEK inhibitor resistance mechanism 
involves amplification of the driving oncogene. For example, resistance to MEK inhibitor 
selumetinib was driven by analogous mechanisms in two separate colon cancer cell lines (Little 
et al., 2011). In drug-resistant COLO-205 (BRAFV600E) clones, increased abundance of BRAF 
was the result of BRAF amplification. Similarly, in drug-resistant HCT-116 (KRASG13D) clones, 
elevated KRAS abundance was due to KRAS amplification (Little et al., 2011). In the same vein, 
BRAF amplifications were found in two additional colorectal cancer cell lines (COLO201 and 
COLO206F) with BRAFV600E mutations when chronically exposed to selumetinib (Corcoran et 
al., 2010). Increased abundance of activated KRAS confers resistance to MEK inhibitor CI-1040 
was demonstrated in C26 murine colon cancer cells, which harbor KRASG12V (Wang et al., 
2005). 
Since ERK inhibitors have only recently reached the clinic, there is limited data on the 
mechanisms of resistance to ERK inhibition. A study by Jha et al. sought to preemptively define 
modes of resistance to ERK inhibition (Jha et al., 2016). Chronic exposure of the HCT-116 
(KRASG13D) cell line to ERK inhibitor SCH772984 led to emergence of a G186D mutation in 
ERK1, which impairs binding to the ERK inhibitor. 
In sum, a multitude of resistance mechanisms have been identified for the inhibition of 
each signaling module in the RAF-MEK-ERK pathway. Further validation of each of these 
mechanisms in clinical samples is warranted to justify rational drug combination design to 
prevent or delay tumor recurrence.  
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Melanoma is an excellent disease model for studying RAS-RAF-MEK-ERK signaling and 
therapeutic resistance 
 
Melanoma is a malignancy that arises from melanocytes, the melanin-producing cells 
that reside in a number of different anatomic sites including skin, mucosal epithelia, and 
meninges (Sullivan et al., 2015). For historical reasons, unless otherwise unspecified, 
melanoma normally refers to “skin cutaneous melanoma”, which is the most common form of 
the disease, and also a focus of this dissertation. 
The incidence rate of melanoma has been steadily rising over past few decades (Siegel 
et al., 2015). Well-known as a very aggressive disease, it accounts for 75% of all skin cancer 
deaths. According to the SEER (Surveillance, Epidemiology, and End Results) statistics of the 
National Cancer Institute, melanoma is currently the sixth most common cancer in the United 
States, with an estimated 73,870 new cases and 9,940 deaths in 2015. Although the 5-year 
survival rate for localized melanoma is 98.3%, once metastasized, it plummets to 16.6%. 
Advances in deep-sequencing technologies have contributed dramatically to the in-depth 
understanding of melanoma. Since the publication of the first melanoma genome in 2010 
(Pleasance et al., 2010), subsequent large-scale sequencing studies have discovered 
numerous previously unknown melanoma-associateed genes involved in the regulation of the 
RAS-RAF-MEK-ERK and other signaling pathways (Cancer Genome Atlas, 2015; Hodis et al., 
2012; Krauthammer et al., 2012; Stark et al., 2012). It is now widely accepted that, based on 
genomic classification, melanomas are divided into four major subtypes: mutant BRAF, mutant 
RAS, mutant NF1, and Triple-WT (wild-type) (Cancer Genome Atlas, 2015) (Figure 1.6). Focal 
amplifications of BRAF were observed at significant frequencies in the BRAF mutant subtype, 
whereas NRAS amplifications co-occurred in tumors with NRAS mutations (Cancer Genome 
Atlas, 2015). Among a collection of 318 tumor samples analyzed, the mutation frequencies of 
BRAF, RAS and NF1 were 52%, 30%, and 14%, respectively (Cancer Genome Atlas, 2015), 
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indicating that the vast majority of melanomas have hyperactivation of the RAS-RAF-MEK-ERK 
pathway. 
Melanoma is distinct in its “choice” of RAS mutation. As introduced earlier, while most 
cancers preferentially harbor mutations in KRAS, melanomas exhibit a strong bias towards 
NRAS mutations (94%), compared to KRAS (2%) or HRAS (4%) (Cox et al., 2014). 
Furthermore, in contrast to acute myeloid leukemia (AML), which also favors NRAS mutations, 
melanomas preferentially harbor mutations at codon Q61, rather than at G12 or G13 (Burd et al., 
2014; Johnson et al., 2014). Most studies on the roles of wild-type RAS isoforms in RAS-mutant 
cancers to date have focused on KRAS mutant disease, likely due to the prevalence of 
mutations in this isoform (Grabocka et al., 2014; Jeng et al., 2012; Lim et al., 2008; Weyandt et 
al., 2015). Owing to their distinct biological functions in cancers (Castellano and Santos, 2011), 
observations from KRAS-mutant cancers may not apply to cancers with another mutated RAS 
isoform. Therefore, interrogating the contributions of wild-type RAS in different mutant-isoform 
system, such as NRAS-mutant diseases, is desired. Hence, NRAS-mutant melanoma is a 
naturally occurring disease model that is highly suitable for the study of RAS isoform 
interactions in a new mutant-isoform setting. Moreover, NRAS mutations are an independent 
prognostic indicator for worse clinical outcomes (Devitt et al., 2011; Jakob et al., 2012; Mann et 
al., 2013), and this subgroup does not have access to any FDA-approved targeted therapy. 
There is thus a strong urge to better understand this subpopulation of melanoma patients so as 
to improve their prognosis. 
BRAF-mutant melanoma patients, on the contrary, are currently treated with 4 out of all 
7 FDA-approved inhibitors of RAS effector signaling:  BRAF inhibitors vemurafenib or 
dabrafenib, and MEK inhibitors trametinib and cobimetinib, sometimes in combination (Bollag et 
al., 2010; Chapman et al., 2011; Flaherty et al., 2012a; Flaherty et al., 2012b; Hauschild et al., 
2012; Larkin et al., 2014).  Even so, they face one of the greatest challenges in targeted therapy 
– resistance. As discussed in detail above, both intrinsic and acquired resistance can account 
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for tumor relapse, and there are many possibilities as to how a secondary tumor develops. 
Therefore, because of the extensive use of targeted agents in this genetic subtype, and due to 
the inevitable occurrence of tumor relapse, BRAF-mutant melanoma presents a suitable 
disease model to study therapeutic resistance to inhibitors of the RAS-RAF-MEK-ERK pathway. 
 
Rationale and objectives for this project 
Define a novel mode of resistance to RAF-MEK-ERK pathway inhibition 
Considerable efforts have been invested in identifying resistance mechanisms of BRAF-
mutant melanomas to BRAF inhibition (Hartsough et al., 2014; Lito et al., 2013; Spagnolo et al., 
2015). Interestingly, the literature also provides some evidence that a given resistance 
mechanism can occur in the same or in different tumor types treated with different inhibitors of 
the same pathway (Corcoran et al., 2010; Duncan et al., 2012; Emery et al., 2009; Johannessen 
et al., 2010; Johannessen et al., 2013; Little et al., 2011; Nazarian et al., 2010; Shi et al., 
2012a). Therefore, I hypothesized that some mechanisms of resistance can be shared by 
different drugs that target the same pathway, or even by different diseases that show 
hyperactivity of the same pathway.  
Previously, we identified CK2α as a synthetic lethal partner of ERK inhibition in 
pancreatic ductal adenocarcinoma cells (Hayes et al., 2016). Given that the RAS-RAF-MEK-
ERK pathway is strongly activated in both pancreatic cancer and melanoma, we sought to 
determine whether CK2α also plays a role in resistance to inhibition of this pathway in 
melanoma. To this end, I defined the GI50 values of approved single agent therapies 
(vemurafenib, dabrafenib, and trametinib) in BRAFV600E melanoma cells ectopically expressing 
CK2α, or depleted of endogenous CK2α. I also monitored reactivation of ERK phosphorylation 
as a readout for emergence of resistance (Solit et al., 2006). Work from this study sheds light on 
the role of a novel candidate of resistance, CK2α, in modulating RAF-MEK-ERK signaling. 
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Define the roles of wild-type RAS isoforms in the presence of oncogenic NRAS 
There is mounting evidence to suggest an important and sophisticated role of wild-type 
RAS isoforms in oncogenic RAS-driven tumor development. However, studies come to different 
conclusions as to whether they play a tumor-suppressive or tumor-supporting role, suggesting 
context dependency (tumor type, stage of tumor development, specific oncogenic RAS isoform) 
(Jeng et al., 2012; Lim et al., 2008; To et al., 2013; Young et al., 2013). In addition, reported 
mechanisms of interplay between wild-type and oncogenic RAS are diverse, suggesting not 
only context dependency, but also complexity of their interaction, which is likely an integration of 
multiple mechanisms. However, little is known about whether NRAS-mutant cancers require 
KRASWT or HRASWT for tumor initiation and/or maintenance. NRAS mutations preferentially 
occur in cutaneous melanomas, an aggressive and common skin cancer, whose incidence is 
still on the rise. NRAS-mutant melanoma patients, who constitute approximately 28-30% of the 
melanoma population (Cancer Genome Atlas, 2015), not only have worse prognosis than other 
genetic subtypes, but also lack accessibility to targeted therapeutics. My goal was to determine 
whether NRAS-mutant melanomas need wild-type KRAS and/or HRAS for cancer cell survival, 
proliferation or transformed growth. In addition, I aimed to define the mechanisms by which wild-
type RAS proteins sustain such phenotypes. I further used an unbiased reverse phase protein 
array (RPPA) approach to gain molecular insights into isoform-specific regulation of protein 
activation states. Findings from this study inform us about isoform-selective signaling and 
functions of RAS proteins in an NRAS-mutant background. 
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Figure 1.1. The RAS GTPase cycle. RAS cycles between a GDP-bound, inactive state, and a 
GTP-bound, active state, in which it can signal to its downstream effectors. GDP release is 
accelerated by guanine nucleotide exchange factors (GEFs), whereas GTP hydrolysis is 
facilitated by GTPase accelerating proteins (GAPs). 
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Figure 1.2. Overall domain structure of RAS isoforms. The three RAS genes (HRAS, NRAS, 
KRAS) encode four 188-189 amino acid proteins (HRAS, NRAS, and splice variants KRAS4A 
and KRAS4B) that share 82-90% sequence identity. RAS proteins consist of a structured 
globular G domain, a conserved effector domain (E), and an unstructured hypervariable region 
(HVR) that serves as the major membrane targeting region. The sequences in the C-terminal 
CAAX motif dictate prenylation and post-prenyl processing, whereas the elements upstream of 
the CAAX motif include "second signals" such as a polybasic region (PBR), cysteine acceptor 
sites for palmitoylation and serine acceptor sites for phosphorylation. (Adapted from Zhou et al. 
Posttranslational modifications of small G proteins. Springer-Verlag Wien. 2014:99-131) 
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Figure 1.3. RAS effector signaling pathways. The RAF-MEK-ERK, PI3K-AKT-mTOR, 
RalGEF-Ral-TBK1, Tiam1-Rac-PAK, PLCε-PKC, RASSF-Mst1 pathways are 6 RAS effector 
pathways are implicated in RAS-driven oncogenesis. 
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Figure 1.4. The PI3K-AKT-mTOR-S6K pathway. The direct RAS effector phosphatidylinositol-
4,5-bisphosphate 3-kinase (PI3K) converts PIP2 into PIP3, the latter recruiting AKT to the 
plasma membrane. PIP3 can be dephosphorylated to PIP2 by phosphatase and tensin homolog 
(PTEN). Upon translocation to the plasma membrane, AKT can be phosphorylated by PDK1 on 
its activation loop (T308), which is sufficient to activate the mammalian target of rapamycin 
complex 1 (mTORC1) by direct phosphorylation on Ser2448. Activation of mTORC1 results in 
increased protein synthesis and cell survival due to phosphorylation of its effectors, such as 4E-
BPs (elF4E-binding proteins) and p70 ribosomal S6 kinases (S6K1 and S6K2), and 
consequently of their major targets including several residues of ribosomal protein S6 (rpS6).  
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Figure 1.5. Scaffolds and negative feedback signaling fine-tune RAS-RAF-MEK-ERK 
signaling outcome. The kinase suppressor of RAS 1 (KSR1) scaffold protein facilitates the 
assembly of RAF, MEK and ERK to enhance signaling efficiency. Rapid and direct feedback by 
inhibitory phosphorylation on SOS, BRAF, CRAF and MEK1 by ERK1/2, and in some cases, the 
ERK1/2 effector p90 RSK, limits signal transduction through the pathway. ERK1/2 activation 
induces the transcriptional expression of ERK-specific dual-specificity phosphatases (DUSPs) 
and Sprouty (SPRY) proteins. Nuclear DUSP5 and cytoplasmic DUSP6 directly 
dephosphorylate and inactivate ERK1/2. SPRY proteins are recruited to the plasma membrane 
upon growth factor stimulation, and interfere with RTK coupling to RAS. 
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Figure 1.6. Mechanisms of resistance to BRAF inhibition lead to ERK1/2 reactivation. 
Mutations in NRAS at residue Q61 and in MEK1 at several sites are known to confer resistance 
to BRAF inhibition. Upregulation of receptor tyrosine kinase signaling, increased expression of 
CRAF and COT, and amplifications in BRAFV600E, also promote BRAF inhibitor resistance. A 61 
kDa, alternatively spliced form of BRAFV600E (p61) lacking exons 4-8 (encoding the RAS binding 
domain of BRAF) dimerizes independently of RAS, thereby facilitating signaling through its wild-
type RAF partner. 
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Figure 1.7. BRAF and NRAS mutations in skin cutaneous melanoma. BRAF and NRAS 
mutations account for 52% and 28% of melanoma cases, respectively. BRAF and NRAS 
mutations are largely mutually exclusive (mutual exclusivity p-value < 0.001). Data acquired 
from www.cBioPortal.org (345 samples). 
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CHAPTER II: CK2α  MAINTAINS ERK ACTIVITY TO PROMOTE RESISTANCE TO 
INHIBITORS OF THE RAF-MEK-ERK PATHWAY IN BRAF-MUTANT MELANOMA 
 
Overview 
The protein kinase CK2 is a pleiotropic and constitutively active kinase that plays crucial 
roles in cellular proliferation and survival.  Overexpression of CK2, particularly the alpha 
catalytic subunit (CK2α, CSNK2A1), has been implicated in a wide variety of cancers and is 
associated with poorer survival and with resistance to both conventional and targeted anticancer 
therapies. Here, we found that CK2α protein is elevated in melanoma cell lines compared to 
normal human melanocytes. We then tested the involvement of CK2α in drug resistance to 
FDA-approved single-agent targeted therapies for melanoma. In BRAF-mutant melanoma cells, 
ectopic CK2α decreased sensitivity to vemurafenib (BRAFi), dabrafenib (BRAFi), and trametinib 
(MEKi), by a mechanism distinct from that of mutant NRAS. Conversely, knockdown of CK2α 
sensitized cells to inhibitor treatment. CK2α-mediated RAF-MEK kinase inhibitor resistance was 
tightly linked to its maintenance of ERK phosphorylation.  We found that CK2α post-
translationally regulates the ERK-specific phosphatase DUSP6 in a kinase dependent-manner, 
decreasing its abundance.  However, we unexpectedly showed, by using a kinase-inactive 
mutant of CK2α, that RAF-MEK inhibitor resistance did not rely on CK2α kinase catalytic 
function, and both wild-type and kinase-inactive CK2α maintained ERK phosphorylation upon 
inhibition of BRAF or MEK. That both wild-type and kinase-inactive CK2α bound equally well to  
 
This chapter is currently under revision for publication. The author list is as follows: Bingying 
Zhou, Daniel A. Ritt, Deborah K. Morrison, Channing J. Der, Adrienne D. Cox. All experiments 
were performed by myself except for Figure 2.7, which was done by Daniel Ritt in the laboratory 
of Dr. Deborah Morrison. 
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the RAF-MEK-ERK scaffold KSR1 suggested that CK2α increases KSR facilitation of ERK 
phosphorylation.  Accordingly, CK2α did not cause resistance to direct inhibition of ERK by the 
ERK1/2-selective inhibitor SCH772984 (Morris et al., 2013). Our findings support a kinase-
independent scaffolding function of CK2α that promotes resistance to RAF- and MEK-targeted 
therapies. 
 
Introduction 
The protein kinase CK2 (casein kinase 2 or II), is a highly conserved, ubiquitously 
expressed, pleiotropic, and constitutively active serine/threonine kinase that has crucial roles in 
cell survival, proliferation and differentiation (Pinna, 2002; Pinna and Allende, 2009; Trembley et 
al., 2009). The CK2 holoenzyme consists of two regulatory (beta) and two catalytic (alpha or 
alpha’) subunits, the latter of which can also function independently of the tetramer (Hanif et al., 
2010).  Although CK2 itself does not appear to be a proto-oncogene, its upregulation has been 
shown to promote growth and prevent apoptosis, both of which promote cancer (Trembley et al., 
2009). Indeed, overexpression of CK2 at the transcript and/or protein level has been observed 
in many cancers (Ortega et al., 2014), including multiple myeloma (Piazza et al., 2006), chronic 
lymphocytic leukemia (Martins et al., 2010), breast (Giusiano et al., 2011), colorectal (Lin et al., 
2011) and liver cancers (Zhang et al., 2015), etc., and is correlated with poorer patient survival 
(Bae et al., 2015; Lin et al., 2011; Ortega et al., 2014).  Similarly, CK2 exhibited 2.5-fold higher 
catalytic activity in metastatic melanoma than in dermal nevi (Mitev et al., 1994).  
In addition to its roles in tumor growth and progression, CK2 also promotes drug 
resistance to both conventional and targeted therapeutics. For example, pharmacological 
inhibition of CK2 kinase activity reverted multidrug resistance of a human T lymphoblastoid cell 
line (Di Maira et al., 2007), at least in part by down-regulating P-glycoprotein activity. In addition, 
siRNA-mediated knockdown of CK2 catalytic subunits enhanced chemosensitivity to 
gemcitabine in human pancreatic cancer cells (Kreutzer et al., 2010). In cells depleted of CK2α, 
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gemcitabine induced MKK4/JNK signaling, resulting in cell death (Kreutzer et al., 2010). Further, 
CK2 displayed elevated protein expression and activity in chronic myeloid leukemia cells that 
are resistant to the small molecule kinase inhibitor imatinib (Borgo et al., 2013). Either reduction 
of CK2α expression or pharmacological inhibition of CK2α kinase activity restored imatinib 
sensitivity, possibly through suppressing Akt activity (Borgo et al., 2013). However, the role of 
CK2α in drug resistance, particularly to targeted therapeutics, has remained underexplored. 
Inhibitors of BRAF and MEK, members of the RAF-MEK-ERK kinase cascade, have 
achieved remarkable overall response rates in advanced melanomas harboring BRAF V600 
mutations, yet a significant proportion of patients is intrinsically resistant to such therapies, and 
those who respond almost inevitably develop resistance over a matter of months (Menzies and 
Long, 2014).  Considerable efforts have been invested in identifying resistance mechanisms of 
BRAF-mutant melanomas to BRAF inhibition, and some have demonstrated clinical relevance 
(Lito et al., 2013; Spagnolo et al., 2014; Sullivan and Flaherty, 2013; Wang et al., 2015). In a 
recent whole-kinome siRNA screen for kinases that could induce resistance to ERK kinase 
inhibitors in pancreatic ductal adenocarcinoma cells, we identified CK2α as a synthetic lethal 
partner of ERK inhibition (Hayes et al., 2016). We postulated that kinase inhibitor resistance 
mechanisms can be shared by diseases that show hyperactivity of the same pathway. Given 
that the RAF-MEK-ERK pathway is strongly activated in both pancreatic cancer and melanoma, 
we sought to determine whether CK2 also plays a role in resistance to inhibition of this pathway 
in melanoma.  
In the present study, we found that CK2α overexpression was sufficient to drive 
resistance to both BRAF and MEK inhibitors in BRAF-mutant melanoma cells. Conversely, 
depletion of CK2α increased sensitivity to the BRAF inhibitor vemurafenib. Consistent with 
these results, CK2α sustained ERK phosphorylation under conditions of pathway inhibition. 
Although we found that CK2 negatively regulated expression of the ERK-specific phosphatase 
DUSP6 in a kinase-dependent manner, yet the maintenance of ERK phosphorylation was not 
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due to these decreased levels of DUSP6. Instead, we found that CK2α-mediated maintenance 
of ERK phosphorylation and drug resistance were kinase-independent.  The ability of both wild-
type and kinase-inactive CK2α to bind to the key RAF-MEK-ERK pathway scaffold protein 
KSR1, that is required for optimal ERK phosphorylation and activation, supports a kinase-
independent scaffolding role for CK2α in facilitating optimal ERK signaling under conditions of 
pathway inhibition. That CK2α overexpression did not cause resistance to a direct ERK inhibitor 
is further evidence that ERK inhibition may overcome resistance mechanisms that shorten the 
effectiveness of blocking upstream kinases in the RAF-MEK-ERK pathway. 
 
Experimental procedures 
Cell culture and reagents 
A375, A2058, Sbc12A, Malme-3 and 293T cell lines were grown in DMEM-H 
supplemented with 10% FBS (HyCloneTM, Thermo Scientific) and 1% gentamycin/kanamycin 
(Tissue Culture Facility (TCF), Lineberger Comprehensive Cancer Center (LCCC), University of 
North Carolina at Chapel Hill (UNC-CH)). SK-MEL-28 and RPMI-7951 were grown in MEM-
Alpha (Gibco) supplemented with 10% FBS and 1% gentamycin/kanamycin. Normal human 
melanocyte pellets were kindly provided by Dr. William Kaufmann, UNC-CH. The BRAFi 
vemurafenib (PLX4032) was a generous gift from Gideon Bollag (Plexxikon).  The BRAFi 
dabrafenib (GSK2118436) MEKi trametinib (GSK1120212) were purchased from Selleckchem. 
MG132 was purchased from Calbiochem (#474790). 
 
Plasmid constructs and gateway cloning 
The CK2α expression construct, pDONR223-CSNK2A1 (Human ORFeome v5.1), was 
purchased from UNC's TCF. pHAGE-FLAG (N-terminal tag) empty vector was a generous gift 
from Ben Major, UNC-CH. Both CK2α and NRAS(Q61K) were cloned into the pHAGE-FLAG 
vector by Gateway cloning using LR Enzyme Clonase Mix (Invitrogen), according to the 
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manufacturer’s protocol. A set of five shRNAs targeting CK2α (CSNK2A1) in pLKO.1 vector was 
purchased from the Lenti-shRNA Core Facility at UNC-CH.  Target sequences are indicated 
below.  
shRNA TRC Clone ID Target sequence 
#1 TRCN0000000606 5’-GCTGCATTTAGGTGGAGACTT-3’ 
#2 TRCN0000000607 5’-CGTAAACAACACAGACTTCAA-3’ 
#3 TRCN0000000608 5’-CAAGAATATAATGTCCGAGTT-3’ 
#4 TRCN0000000609 5’-AGAATTTGAGAGGAGGTCCCA-3’ 
#5 TRCN0000000610 5’-CCAAGAATATAATGTCCGAGT-3’ 
 
Lentivirus production and infection 
To produce lentivirus, 293T cells were transfected with pHAGE vector-based GFP, CK2α 
or NRAS(Q61K), in combination with psPAX2 and pMD2.G, at a ratio of 4:3:1. After overnight 
transfection, the culture medium was changed to DMEM-H supplemented with 20% FBS. Thirty-
six hours later, viral supernatants were harvested and filtered through a sterile 0.45 µm filter to 
remove cell debris. Cleared supernatants were aliquotted and frozen at -80°C until use. Cells 
were infected with 500 µl virus in 5 µg/ml polybrene (Millipore) overnight. Selection of 
transduced cells in puromycin (1 µg/ml or 2 µg/ml for A375 or SK-MEL-28 cells, respectively) 
was complete at 48 h after infection. 
 
Western blotting 
Cells were washed twice with ice-cold PBS and lysed in RIPA buffer (150 mM NaCl, 1% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0) containing 1X protease 
inhibitors (BaculoGoldTM Protease Inhibitor Cocktail, BD Biosciences, #51-21426Z) and 1× 
phosphatase inhibitors (HaltTM Phosphatase Inhibitor Cocktail, Thermo Scientific, #78420). 
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Lysates were depleted of cell debris by centrifugation at maximum speed (4°C, 10 min), then 
proteins were quantified by Bradford assay (DCTM Protein Assay, Bio-Rad), normalized, 
reduced, denatured at 95 °C for 5 min, and resolved by SDS gel electrophoresis. Proteins were 
transferred to PVDF membranes (Millipore, #IPFL00010) and probed with primary antibodies 
recognizing pERK (Cell Signaling, #4370), ERK (Cell Signaling, #9102), pMEK (Cell Signaling, 
#9154), pRSK (Cell Signaling, #9344), DUSP6 (Abcam, ab54940), beta-actin (Sigma, A5316), 
CK2α (Santa Cruz, sc-373894), FLAG-tag (Sigma, F3165; Novus, NBP1-06712SS), or GFP 
(Roche, 11814460001). A rabbit antibody to the phosphorylated CK2α substrate EEF1D was a 
generous gift from David W. Litchfield (Western University). A rabbit-anti KSR1 antibody 
(Morrison Lab) was used to detect KSR1 following immunoprecipitation. After incubation with 
the appropriate secondary anti-mouse (GE Healthcare, NA931V) or anti-rabbit (GE Healthcare, 
NA934V) antibody, proteins were detected by chemiluminescence (Thermo Scientific, #34075). 
Blots were developed by exposure to X-ray film, or by the ChemiDocTM MP Imaging System 
(Bio-Rad) for quantification. 
 
Pharmacologic growth inhibition (GI50) assay 
Growth inhibition assays were performed as described previously (Johannessen et al., 
2013; Nazarian et al., 2010) with minor modifications. Cultured cells were seeded into 96-well 
plates (2,000 cells per well). Sixteen hours after seeding (baseline), serial dilutions of inhibitors 
were prepared in DMSO and added to cells, yielding final drug concentrations ranging from 1 
nM to 10 µM for vemurafenib, dabrafenib and SCH772984, 0.1 nM to 1 µM for trametinib, with 
the final volume of DMSO not exceeding 1%. Cells were incubated for 72 h following addition of 
drug. To measure cell proliferation, 5 mg/ml MTT (Sigma-Aldrich, #M5655) was added 1:10 into 
wells, and incubated at 37°C for 4 h. Formazan products were solubilized using acidified 
isopropanol (0.04N HCl in isopropanol), and absorbance was measured at 562 nm, with a 
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background subtraction at 650 nm. Percent cell growth under each condition was calculated as 
follows: Cell growth (%)=100×(T-T0)/(C-T0), where T0 is absorbance at baseline, T is 
absorbance of drug-treated wells at 72 h, C is absorbance of DMSO-treated wells at 72 h. A 
minimum of three replicates was performed for each cell line and drug combination. Data from 
growth inhibition assays were modeled using a non-linear regression curve fit with a sigmoidal 
dose-response (GraphPad Prism, v5.0c). The resulting curves were displayed, and GI50 values 
were also generated, using GraphPad Prism. 
 
Clonogenic assay 
Clonogenic assays were performed as described previously (Franken et al., 2006) with 
slight modifications. Briefly, cells were plated in duplicate wells at 100 cells/well in 6-well plates, 
and allowed to adhere for 3 h at 37°C, after which culture medium was carefully removed and 
replaced with medium containing either DMSO vehicle control or inhibitor. Two weeks following 
drug treatment, cells were washed once with PBS, then fixed and stained with crystal 
violet/paraformaldehyde for 30 min at room temperature. Stain was decanted, and plates were 
carefully rinsed with distilled water, until background staining of the wells was minimized. 
Finally, plates were air-dried, and colonies were counted manually using a cell counter. 
 
Site-directed Mutagenesis 
Site-directed mutagenesis of CK2α was performed using QuikChange II XL Site-Directed 
Mutagenesis Kit (Agilent). A forward primer 5’- 
GCCATCAACATCACAAATAATGAAAAAGTTGTTGTTATGATTCTCAAGCCAG -3’ and reverse 
primer 5’- CTGGCTTGAGAATCATAACAACAACTTTTTCATTATTTGTGATGTTGATGGC -3’ 
were used to introduce a catalytic site mutation (K68M) into pDONR223-CSNK2A1, with bolded 
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nucleotides showing the site of mutagenesis. Reaction conditions strictly followed the 
manufacturer’s protocol. 
 
RNA isolation, reverse transcription and real-time PCR  
Total RNA was isolated from cells using Thermo RNA kit (Thermo Scientific), and then 
0.5 µg total RNA was reverse transcribed to generate cDNA using iScriptTM cDNA Synthesis Kit 
(Bio-Rad) according to the manufacturer’s instructions. Real-time PCR was performed using the 
SsoFastTM EvaGreen® Supermix (Bio-Rad) on the Bio-Rad CFX-96 Real-Time PCR System. 
Beta-actin was used for normalization. DUSP6 was amplified using forward primer 5’-
CGACTGGAACGAGAATACGG-3’ and reverse primer 5’-TTGGAACTTACTGAAGCCACCT-3’. 
 
Co-immunoprecipitation 
Co-immunoprecipitation assays were performed as described previously (Ritt et al., 
2007). In brief, two 10 cm dishes of A375 cells were washed twice with cold PBS and lysed in 
1% NP-40 buffer (20 mM Tris [pH 8.0], 137 mM NaCl, 10% glycerol, 1% NP-40 alternative, 0.15 
U/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM sodium vanadate, 20 µM leupeptin) 
using 600 µl lysis buffer/10 cm dish.  The lysates were clarified by centrifugation and equivalent 
amounts of protein lysate were incubated with a mouse-anti-human KSR1 antibody (Sigma-
Aldrich, WH0008844M1) and protein G sepharose beads for 3 h at 4 °C. Immunoprecipitated 
complexes were collected by centrifugation, washed extensively with 1% NP-40 buffer and then 
examined by immunoblot analysis. 
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Results 
CK2α expression is upregulated in a subset of melanomas 
To examine the expression of CK2α in melanoma, we first surveyed the Cancer Genome 
Atlas (TCGA) skin cutaneous melanoma dataset for CK2α mRNA expression through cBioPortal 
(http://www.cbioportal.org). We found that the CK2α transcript is upregulated in a subset of 
those tumors (15% of 278 samples), and that 90% of that subset also harbor mutations in 
BRAF, NRAS and/or NF1 that lead to hyperactivation of ERK.  Next, we measured CK2α protein 
expression in a panel of normal human melanocytes (NHMs) and melanoma cell lines (5 BRAF-
mutant: A375, SK-MEL-28, A2058, RPMI-7951, Malme-3; and 1 NRAS-mutant: Sbc12A). 
Compared to NHM, all of the melanoma cell lines had higher levels of CK2α protein expression 
(Figure 2.1). Like the melanoma patient samples evaluated by TCGA, BRAF- and NRAS-mutant 
melanoma cell lines also exhibit ERK hyperactivation (Shields et al., 2007; Solit et al., 2006).  
 
CK2α promotes resistance to inhibitors of BRAF and MEK in BRAF-mutant melanoma 
cells 
 
We recently used a whole-kinome siRNA screen to search for mechanisms of resistance 
to ERK inhibition in pancreatic ductal adenocarcinoma cells, and found that CK2α was one of 
the hits identified (Hayes et al., 2016). To test whether CK2α promotes resistance to 
conventional RAF-MEK-ERK pathway inhibition in melanoma cells with hyperactivation of this 
pathway, we first stably expressed FLAG-tagged wild-type CK2α in A375 melanoma cells 
(Figure 2.2A,B). These cells possess a homozygous BRAF(V600E) mutation and are  sensitive 
to both BRAFi and MEKi. We then assessed sensitivity to growth inhibition by multiple inhibitors 
of the pathway, including mutant BRAF-selective inhibitors vemurafenib and dabrafenib, and 
MEK1/2-selective inhibitor trametinib. Oncogenically activated (mutant) NRAS has been 
identified in patients with BRAF-mutant melanomas as one mechanism of resistance to BRAF 
but not MEK inhibition (Nazarian et al., 2010).  Therefore, we stably expressed FLAG-tagged 
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mutant NRAS(Q61K) (Figure 2.2A) as a positive control. Neither CK2α nor mutant NRAS 
increased the already high basal level of ERK phosphorylation (Figure 2.2C).  But, as expected, 
mutant NRAS promoted resistance to both BRAF inhibitors vemurafenib and dabrafenib, as 
evidenced by increased values for 50% growth inhibition (GI50) of 5.5-fold and 4.4-fold, 
respectively, compared to the GFP negative control (Figure 2.2D). In contrast, mutant NRAS 
only mildly increased the GI50 (1.7-fold) for the MEKi trametinib, consistent with findings that 
BRAF-mutant melanomas with secondary NRAS mutations still remain sensitive to MEK 
inhibition (Nazarian et al., 2010). Notably, expression of CK2α increased the GI50 for 
vemurafenib, dabrafenib, and trametinib by 4.7-fold, 3.8-fold and 7.4-fold, respectively, 
indicating reduced sensitivity to all three inhibitors (Figure 2.2D). Expression of CK2α also 
produced resistance to vemurafenib in another BRAF-mutant melanoma cell line, SK-MEL-28 
(data not shown). To further evaluate the effect of CK2α expression on responses to the 
abovementioned inhibitors, we performed clonogenic cell survival assays. Consistent with the 
increased GI50 values, CK2α enhanced the clonogenic survival of A375 cells in the presence of 
each inhibitor (Figure 2.2E). In contrast to CK2α, NRAS(Q61K) significantly enhanced 
clonogenic survival only in response to vemurafenib. The modest enhancement in clonogenic 
survival in response to dabrafenib did not reach statistical significance. Together, these results 
indicate that CK2α overexpression, but not NRAS mutation, is sufficient to induce resistance to 
both BRAF and MEK inhibition, which implies a CK2α-mediated resistance mechanism distinct 
from that mediated by mutant NRAS. 
 
CK2α depletion sensitizes melanoma cells to BRAF inhibition 
Given that CK2α overexpression was sufficient to drive resistance, we asked whether, 
conversely, depletion of CK2α would enhance sensitivity to pathway inhibition. We employed a 
set of five shRNAs (#1-#5) to knock down CK2α in A375 cells.  Complete knockdown of CK2α 
was incompatible with cell survival (data not shown).  Therefore, to obtain cells for subsequent 
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experimentation, we utilized shRNAs #4 and #5, which yielded ~60% knockdown and sufficient 
viability (Figure 2.3A). Even this incomplete depletion of CK2α expression resulted in decreased 
GI50 for vemurafenib (55% and 65% decrease for shRNAs #4 and #5, respectively; Figure 2.3B). 
This result indicates that CK2α overexpression is necessary for resistance to BRAF inhibition. 
 
CK2α sustains ERK phosphorylation under conditions of RAF-MEK-ERK pathway 
inhibition 
 
Previous studies have identified multiple mechanisms of resistance to BRAF inhibition, 
the majority of which are characterized by ERK reactivation (Solit and Rosen, 2014). Given that 
CK2α and mutant NRAS both promote BRAFi resistance, we hypothesized that they are both 
capable of facilitating ERK reactivation following inhibition of BRAF and/or MEK. As anticipated, 
mutant NRAS induced strong ERK reactivation upon inhibition of BRAF with either vemurafenib 
or dabrafenib (Figure 2.4A,B). CK2α also facilitated ERK rebound, though not as strongly as 
NRAS(Q61K). Consistent with their trametinib resistance profiles, NRAS(Q61K) failed to 
reactivate ERK in the presence of trametinib, while CK2α did sustain ERK phosphorylation 
(Figure 2.4C). The maintenance of ERK phosphorylation by CK2α suggested either maintained 
upstream activation, or suppressed deactivation mechanisms. MEK is the only known direct 
activator of ERK (Crews et al., 1992), and phosphorylation of MEK at Ser217 and Ser221 is 
indicative of MEK activation. DUSP6/MKP3 (dual specificity phosphatase 6/MAP kinase 
phosphatase 3) is a key ERK-specific phosphatase that reverses MEK phosphorylation at the 
TEY motif of ERK (Muda et al., 1996). Therefore, we assessed the status of both MEK 
activation and DUSP6 expression by western blotting. We found that CK2α accelerated the 
rebound of MEK activation upon MEK inhibition (Figure 2.4C). Intriguingly, DUSP6 expression 
was also strongly reduced in CK2α-overexpressing cells even without inhibitor treatment (Figure 
2.4C). Based on this finding, we initially hypothesized that downregulation of DUSP6 contributed 
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to the sustained ERK phosphorylation. However, we first needed to confirm whether CK2α truly 
regulates DUSP6 expression. 
 
CK2α regulates DUSP6 protein levels in a kinase-dependent manner 
CK2α has been reported to directly phosphorylate DUSP6 at multiple sites in vitro, the 
consequences of which are largely unknown (Castelli et al., 2004). To control for CK2α kinase 
activity, we generated a kinase-inactive mutant of CK2α (Ji et al., 2009), and measured DUSP6 
protein levels upon ectopic expression of either kinase-inactive (K68M) or wild-type (WT) CK2α. 
As expected, CK2α(WT) was constitutively active, and cells overexpressing this form of CK2α 
exhibited elevated basal phosphorylation of EEF1D (Figure 2.5A), a validated marker of CK2 
activity (Gyenis et al., 2011). In contrast, cells expressing kinase-inactive CK2α(K68M) exhibited 
mildly reduced levels of EEF1D phosphorylation (Figure 2.5A), suggesting a weak dominant-
negative effect. Interestingly, CK2α(WT) drastically reduced DUSP6 abundance whereas K68M 
did not have an effect (Figure 2.5B), indicating that the decrease in DUSP6 protein is likely due 
to CK2α-mediated phosphorylation. Conversely, shRNA-mediated knockdown of endogenous 
CK2α enhanced DUSP6 protein levels (Figure 2.5C). To determine whether the reduction in 
DUSP6 was the result of accelerated degradation or suppressed transcription, we first used 
MG132 to block proteasome-mediated protein degradation. Six hours after MG132 treatment, 
DUSP6 abundance was fully rescued (Figure 2.5D). We also examined DUSP6 mRNA levels by 
qPCR, and found that they did not change upon CK2α expression (Figure 2.5E). These results 
indicate that CK2α kinase activity regulates DUSP6 abundance by facilitating its proteasomal 
degradation. 
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CK2α-mediated maintenance of ERK phosphorylation and pathway inhibitor resistance 
does not require its kinase function 
 
Given that CK2α kinase activity was essential to the decrease in DUSP6 expression 
(Figure 2.5B), we hypothesized that kinase-inactive CK2α would not be able to maintain ERK 
phosphorylation when the pathway was inhibited. Unexpectedly, the kinase-inactive mutant also 
sustained ERK phosphorylation, comparable to that of the wild-type kinase (Figure 2.6A). We 
therefore anticipated that kinase-inactive CK2α would also promote resistance in a similar 
fashion. Consistent with this, we found that CK2α(K68M) promoted resistance to vemurafenib, 
dabrafenib and trametinib to the same extent as CK2α wild-type (Figure 2.6B), indicating that 
CK2α-mediated BRAFi and MEKi resistance does not depend on its catalytic kinase activity. 
Instead, our findings indicate that the ability of CK2α to maintain ERK phosphorylation when the 
pathway is inhibited and to promote resistance to BRAF and MEK inhibitors is more likely due to 
a protein-binding or scaffolding function of CK2α. 
 
CK2α(WT) and CK2α(K68M) bind equally well to the RAF-MEK-ERK scaffold protein KSR1 
 Our previous work (Ritt et al., 2007) uncovered an essential role of CK2α in maximally 
facilitating RAF-MEK-ERK pathway activation through its direct binding to KSR1 (Kinase 
Suppressor of Ras 1), within the KSR1 scaffolding complex that also includes RAF, MEK and 
ERK. CK2α association with KSR enhances RAF phosphorylation of MEK. Given our finding 
here that kinase-inactive CK2α maintains ERK phosphorylation and resistance to pathway 
inhibitors to the same extent as its wild-type counterpart, we speculated that it too retains 
binding to KSR1. Accordingly, when we immunoprecipitated endogenous KSR1 from A375 
cells, we detected considerable levels of ectopically expressed CK2α(WT) and CK2α(K68M), 
but not the GFP control (Figure 2.7). This result supports our hypothesis that CK2α binding to 
KSR1 is kinase-independent, offering a potential mechanism by which both CK2α(WT) and 
CK2α(K68M) maintain ERK phosphorylation and resistance to BRAF and MEK inhibitors. 
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Specifically, our findings are consistent with a model whereby CK2α binding enhances the 
efficiency of KSR1 scaffolding to facilitate ERK activation.  
 
ERK inhibition avoids CK2α-mediated resistance to RAF-MEK-ERK pathway blockade 
Our model predicts that CK2 α should not be able to cause resistance in melanoma cells 
to an inhibitor downstream of RAF and MEK that acts directly at the level of ERK.  To test this 
model, we evaluated whether CK2α could cause resistance to the ERK inhibitor SCH772984 
(Morris et al., 2013). Consistent with our model, neither CK2α nor NRAS(Q61K) caused 
resistance to the ERKi, as evidenced by the absence of either  increased GI50 (Figure 2.8A) or 
enhanced clonogenic survival (Figure 2.8B). For evidence that the inhibitor correctly hit its ERK 
target, we examined the phosphorylation status of the ERK substrate p90 RSK (Figure 2.8C). 
We (Hayes et al., 2016) and others (Morris et al., 2013) have shown recently that decreased 
phospho-RSK (pRSK) is a more reliable marker of decreased flux through ERK than is ERK 
phosphorylation itself, not least because ERK phosphorylation rebounds quickly whereas pRSK 
does not.  Examination of pRSK in ERKi-treated cells at the same time point (72 h) as the GI50 
analysis revealed that neither overexpressed CK2α nor mutant NRAS was able to restore ERK 
pathway activation in the presence of ERKi.  Thus, although CK2α induces resistance to BRAFi 
and MEKi in a kinase-independent manner, even kinase-intact CK2α does not induce resistance 
to ERKi, which is an effective means of impairing the RAF-MEK-ERK pathway in these BRAF-
mutant melanoma cells.  This finding is similar to other mechanisms that cause resistance to 
RAFi or MEKi in BRAF-mutant melanomas, where ERKi sensitivity is retained (Morris et al., 
2013).  
 
Discussion 
Although targeted therapies in melanoma have substantially improved patient outcomes 
immediately following treatment in a subset of patients, even responsive patients are confronted 
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with the inevitable development of resistance months later (Lito et al., 2013; Spagnolo et al., 
2014; Sullivan and Flaherty, 2013; Zhang, 2015). Understanding the underlying mechanisms of 
innate or acquired resistance is key to developing new combination therapies to overcome 
tumor unresponsiveness or recurrence. In the present study, we demonstrate that abnormally 
elevated expression of the alpha catalytic subunit of protein kinase CK2 (CK2α, CSNK2A1) is 
sufficient to cause resistance to each of three small molecule kinase inhibitors of the RAF-MEK-
ERK pathway approved for treatment of melanoma: vemurafenib, dabrafenib and trametinib. 
Further, we show that this resistance correlates with the rebound/maintenance of ERK activity 
following pathway inhibition.  
The distinct resistance profiles of CK2α and NRAS(Q61K) imply different mechanisms of 
promoting resistance. Specifically, it is known that secondary NRAS mutations that increase flux 
through the RAS-MEK-ERK pathway via CRAF activation can overcome inhibitor potency 
(Nazarian et al., 2010). Such a route of reactivation could easily be blocked by MEK inhibition. 
Consistent with this idea, NRAS(Q61K) did not confer resistance to MEK inhibitor trametinib. 
However, the fact that CK2α-mediated resistance is MEK inhibitor-inert suggests two possible 
mechanisms. The first entails some unknown bypass that leads to sustained ERK 
phosphorylation. This is somewhat unlikely because MEK is still the only known direct activator 
of ERK. The second involves steric hindrance provided by CK2α that prevents a MEK inhibitor 
from binding to its target effectively. Such a mechanism can be provided by a scaffolding 
function of CK2α, as discussed below. 
Intriguingly, we found that wild-type CK2α drastically reduced expression of the dual 
specificity phosphatase 6 (DUSP6), whereas CK2α silencing elevated endogenous DUSP6 
protein levels. DUSP6 is a key ERK-specific phosphatase that negatively regulates the RAF-
MEK-ERK pathway (Muda et al., 1996). Indeed, DUSP6 has been previously reported to 
interact with and to be phosphorylated by CK2α (Castelli et al., 2004). We further show here 
that CK2α-facilitated proteasomal degradation accounts for the decreased abundance of 
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DUSP6 protein. In light of our results, it would be interesting to know whether DUSP6 
expression could serve as a biomarker of CK2 inhibition. 
Much to our initial surprise, we determined, using a kinase-inactive mutant of CK2α, that 
CK2α kinase activity is not required for either CK2α-mediated inhibitor resistance or sustained 
ERK phosphorylation in the context of these BRAF-mutant melanoma cells. This was 
unexpected because CK2 is well-known as a constitutively active kinase that has hundreds of 
endogenous substrates, and its kinase activity has largely been assumed to be responsible for 
its pleiotropic effects (Pinna, 2002; Pinna and Allende, 2009; Trembley et al., 2009). However, 
the whole-kinome screen by which we identified CK2α as a potential resistance mechanism 
capable of inducing at least a 5-fold increase in resistance to ERK inhibitor was not performed 
by inhibition of the catalytic activity of the CK2α kinase, but rather by siRNA-mediated depletion 
of expression of the entire protein (Hayes et al., 2016). Therefore this screen would capture 
effects induced by loss of protein-binding or scaffolding functions as well as by loss of catalytic 
activities of the depleted kinases. 
Our data suggest that the above resistance phenotypes are the result of CK2α-mediated 
protein-protein interactions rather than CK2α kinase activity. Consistent with this notion, we 
reported previously that all subunits of CK2 bind to the RAF-MEK-ERK pathway scaffolding 
protein KSR1 (Ritt et al., 2007), and that binding of the CK2α subunit in particular to KSR1 is 
critical for maximal activation of the pathway (Ritt et al., 2007). However, we had not tested 
whether the kinase activity of CK2α was required. Since we have now found that kinase 
deficiency does not impair CK2α binding to KSR1, we speculate that the catalytic activity-
independent binding of CK2α to KSR1 helps to maintain the integrity and function of the RAF-
MEK-ERK pathway, enabling the sustained ERK phosphorylation observed in the presence of 
overexpressed CK2α even when the pathway is inhibited at the level of RAF or MEK. This 
hypothesis could be further tested in the future once the region of CK2α that mediates KSR1 
binding has been identified, as that would allow interrogation of KSR1-binding-deficient mutants 
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of CK2α, It would also be of great interest to determine whether the onset of BRAFi/MEKi 
resistance in melanoma patients is associated with increased levels of CK2α.  
The importance of CK2α protein-protein interactions versus catalytic kinase activity may 
differ greatly depending on context.  A recent study examined the effects of a CK2α-selective 
kinase inhibitor, CX-4945, on the viability of BRAF-mutant thyroid cancer cell lines and found 
synergism of CX-4945 with both the BRAFi vemurafenib and the MEKi selumetinib (Parker et 
al., 2014), suggesting that the kinase activity of CK2α was important for the response to 
BRAFi/MEKi in this tumor type. Surprisingly, when they compared the combination of 
vemurafenib with CX-4945 or with siRNA directed against CK2α in a patient-derived BRAF-
mutant melanoma cell line, they found an additive effect of each on cell death (Parker et al., 
2014). The equivalent effects on vemurafenib responses of kinase-intact and kinase-inactive 
CK2α that we observed argues that the kinase activity is not important in the vemurafenib 
response of BRAF-mutant melanoma, but it is certainly possible that other genetic differences 
may also affect the relative roles of catalytic activity versus protein-protein interactions.  It is also 
interesting that, while our original siRNA screen identified CK2α as a mediator of resistance to 
ERKi in KRAS-mutant pancreatic ductal adenocarcinoma cells, CK2α did not mediate resistance 
to ERKi in BRAF-mutant melanoma cells.  Clearly much remains to be elucidated about the role 
of CK2α in responses to inhibitors of the RAF-MEK-ERK pathway, a role that is likely to be as 
complex as its hundreds of substrates and numerous biological activities portend.  
In summary, our results identify a role for CK2α in promoting resistance to BRAF and 
MEK but not ERK inhibitors in BRAF-mutant melanoma. We also demonstrate, for the first time 
to our knowledge, a kinase-independent function of CK2α in modulating cellular signaling. 
These findings represent a novel mode of innate resistance to RAF-MEK targeted therapy in 
BRAF-mutant melanoma, which may not be easily addressed by inhibition of the dysregulated 
CK2α kinase. 
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Figure 2.1. CK2α protein expression is elevated in melanoma cell lines compared to 
normal human melanocytes (NHM). Cell lysates from a panel consisting of 3 NHM, 5 BRAF- 
and 1 NRAS-mutant melanoma cell lines were probed for CK2α protein by western blotting with 
anti-CK2α antibody. Alpha-tubulin was used as a loading control. 
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Figure 2.2. Ectopic CK2α promotes resistance to inhibitors of BRAF and MEK. A, A375 
cells were stably infected with lentiviral vectors to ectopically express GFP negative control, or 
FLAG-tagged CK2α or NRAS(Q61K), and cell lysates were subjected to western blot using anti-
FLAG antibody. β-actin served as a loading control. B, To determine the relative expression of 
exogenous versus endogenous CK2α, the A375 cells expressing either FLAG-tagged CK2α or 
GFP were immunoblotted with anti-CK2α antibody. C, Neither CK2α nor NRAS(Q61K) 
increases the already elevated basal level of ERK phosphorylation in A375 cells, as determined 
by western blot using anti-phospho-ERK1/2(T202/Y204) antibody. D, CK2α increases GI50 for 
BRAFi vemurafenib, BRAFi dabrafenib and MEKi trametinib. MTT assays were performed after 
72 h of treatment with 5 different doses of inhibitors, and GI50 curves were generated. Results 
are presented as means ± S.E.M. (n = 6) E, CK2α enhances clonogenic survival of inhibitor-
treated A375 cells. Cells as in the previous panels were grown for two weeks on plastic as 
single colonies in the presence of vemurafenib (1 µM), dabrafenib (100 nM), trametinib (1 nM), 
or DMSO vehicle control. Shown are the percent of colonies formed in the presence of each 
inhibitor relative to the vehicle control. Results are presented as means ± S.E.M. **, p<0.01; *, 
p<0.05. (n = 3) 
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Figure 2.3. Suppression of endogenous CK2α increases sensitivity to the BRAF inhibitor 
vemurafenib. A, Endogenous CK2α was suppressed in A375 cells by using 5 different shRNA 
sequences, and the degree of knockdown was assessed by western blot using anti-CK2 
antibody. β-actin served as a loading control. The percent of knockdown achieved by each 
shRNA directed against CK2α, normalized to the non-targeting (NT) shRNA, is indicated below 
each lane. B, Knockdown of ~60% of endogenous CK2α (panel A) is sufficient to decrease the 
GI50 for vemurafenib. GI50 curves for A375 cells infected with either NT or shRNA#4 (black 
dashed line) or shRNA#5 (black dotted line) are shown. Results are presented as means ± 
S.E.M. (n = 3) 
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Figure 2.4. Overexpressed CK2α accelerates ERK rebound or sustains ERK 
phosphorylation in response to RAF-MEK-ERK pathway inhibition. Phosphorylated ERK 
(pERK1/2) was evaluated by western blot analysis of lysates from A375 cells ectopically 
expressing GFP, CK2α or NRAS(Q61K), treated for 24, 48 or 72h with A, vemurafenib (BRAFi, 
1 µM); B, dabrafenib (BRAFi, 100 nM), or C, trametinib (MEKi, 1 nM). Total ERK1/2 served as a 
loading control. MEKi (trametinib)-treated cell lysates were additionally immunoblotted for 
phospho-MEK1/2 (pMEK) and for the ERK1/2-specific phosphatase DUSP6. 
 
  
 56 
 
Figure 2.5. CK2α decreases protein stability of the ERK phosphatase DUSP6 in a kinase-
dependent manner. A, Phosphorylation of the CK2α substrate EEF1D upon expression of wild-
type (WT) or kinase-inactive (K68M) CK2α was detected by western blotting with a phospho-
EEF1D antibody. B, Levels of endogenous DUSP6 protein were determined by western blot of 
lysates from A375 cells ectopically expressing CK2α(WT) or CK2α(K68M), or C, from A375 cells 
depleted of endogenous CK2α by two different shRNAs (same lysates as shown in Fig. 3A). D, 
To determine whether CK2α regulates DUSP6 protein stability, the same cells as panel B were 
immunoblotted for DUSP6 protein after treatment for 6 h with either the proteasome inhibitor 
MG132 (10 µM) or DMSO vehicle control. E, To determine whether CK2α also regulates 
DUSP6 at the transcriptional level, qRT-PCR analysis of DUSP6 mRNA levels was done on 
cells expressing CK2α(WT) or kinase-inactive CK2α(K68M). Results are presented as means ± 
S.E.M. (n = 3) 
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Figure 2.6. CK2α-mediated maintenance of ERK phosphorylation upon pathway inhibition 
and resistance to BRAFi/MEKi are both kinase-independent.  A, A375 cells ectopically 
expressing GFP, CK2α(K68M) or CK2α(WT) were treated with BRAFi and MEKi as in Fig. 4, 
then lysed and immunoblotted for phosphorylated MEK1/2 (pMEK), phosphorylated ERK1/2 
(pERK1/2), and total DUSP6.  Total ERK1/2 served as loading control. B, Cells were treated as 
in panel A and GI50 curves were generated after 72 h. Results are presented as means ± S.E.M. 
(n = 4) 
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Figure 2.7. Both wild-type and kinase-inactive CK2α interact with the RAF-MEK-ERK 
scaffold protein KSR1. Endogenous KSR1 was immunoprecipitated from A375 cells 
expressing the GFP control, or FLAG-tagged CK2α(WT) or kinase-inactive CK2α(K68M). Whole 
cell lysates and immunoprecipitates were then blotted for the presence of FLAG-CK2α, and 
reprobed for KSR1 to ensure that equal amounts of KSR1 were immunoprecipitated. GFP 
served as a negative control to rule out nonspecific co-immunoprecipitation of the ectopic CK2α 
proteins. (n=2) 
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Figure 2.8.  ERK inhibitor SCH772984 is insensitive to overexpression of CK2α. A, The 
GI50 for ERKi SCH772984 is unchanged by overexpression of CK2α or by mutant NRAS.  GI50 
curves were generated after 72 h of ERKi treatment. Results are presented as means ± S.E.M. 
(n = 3)  B, Clonogenic survival in the presence of ERKi is not enhanced by overexpressed CK2α 
or mutant NRAS.  Shown are the percent of colonies formed by A375 cells expressing GFP, 
CK2α or NRAS(Q61K) and treated with ERKi (100 nM) normalized to DMSO vehicle control. 
Results are presented as means ± S.E.M. (n = 3). C, ERKi treatment shuts down ERK pathway 
signaling, as indicated by loss of phosphorylated ERK substrate p90RSK (pRSK). A375 cells as 
in panels A and B were treated for 24, 48 or 72 h with 100 nM SCH772984.
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CHAPTER III: AN ESSENTIAL ROLE FOR WILD-TYPE KRAS IN NRAS-MUTANT 
MELANOMA 
 
Overview 
It has now become increasingly clear that wild-type RAS isoforms may also play 
important roles in the development and maintenance of mutant RAS-driven cancers, although 
whether these are tumor-promoting or tumor-suppressive roles appears to be context-
dependent.  This question has largely been studied in KRAS-mutant cancers, and little is known 
about the roles of wild-type RAS isoforms in NRAS-mutant cancers. Here, I show that, in NRAS-
mutant melanoma, which represents 28-30% of all melanoma cases, both wild-type KRAS and 
HRAS isoforms are needed for cell proliferation and survival, and for transformed growth. 
Specifically, I demonstrate that depletion of KRASWT results in G1 cell cycle arrest and induction 
of apoptosis. In line with this phenotype, I find increases in p53 protein levels and its 
downstream targets including p21 and PUMA, which are known mediators of p53-dependent 
cell cycle arrest and apoptosis, respectively. Further, using reverse-phase protein array 
analysis, I uncover an unanticipated role of KRASWT in maintaining rpS6 phosphorylation that is 
likely the result of AKT- and mTOR-independent regulation of the p70 S6 kinase (S6K1). 
Together, my data demonstrate the importance of wild-type RAS isoforms in NRAS-mutant 
melanoma, and provide insights into potential mechanistic explanations for this dependency. 
 
This chapter is currently in preparation for submission for publication. All experiments were 
performed by myself with the exception of Figure 3.4A, which was performed by Mariaelena 
Pierobon in the laboratory of Dr. Emanuel F. Petricoin III. 
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Introduction 
RAS proteins are the founding members of the RAS superfamily of small GTPases, and 
are located at the center of a highly-complicated signaling network that controls many aspects 
of fundamental cellular processes, including cell differentiation, survival and proliferation (Cox 
and Der, 2010). Alongside their critical importance in normal cell physiology, RAS proteins are 
also heavily involved in human disease. In particular, point mutations that result in constitutive 
activation of RAS are found in ~30% of all human cancers (Cox et al., 2014). Since its discovery 
over three decades ago, RAS has never left the center of the stage of cancer research and drug 
discovery. 
 The human genome is home to three RAS genes (HRAS, NRAS, and KRAS), which 
together encode four RAS proteins (HRAS, NRAS, splice variants KRAS4A and KRAS4B). 
These proteins share an overall 82-90% amino acid sequence identity: all of the regions 
required for nucleotide binding and effector interactions are essentially identical. However, they 
differ significantly in a region termed the “hypervariable region” at their C-termini, which is 
critical for their respective lipid modification, and thus determines their distinct membrane 
binding and trafficking kinetics (Cox et al., 2015). As a result, each RAS isoform shares 
overlapping but distinct localizations at the plasma membrane and on endomembranes (Prior 
and Hancock, 2001). This allows RAS engagement of different pools and concentrations of 
activators and effectors, and therefore has been proposed to contribute to isoform-specific 
signaling properties (Omerovic and Prior, 2009; Plowman and Hancock, 2005). Indeed, studies 
have repeatedly demonstrated that RAS proteins are not created equal (Fotiadou et al., 2007; 
Haigis et al., 2008; Parikh et al., 2007; Prior et al., 2012; Whitwam et al., 2007), thus adding 
another layer of complexity and challenge in addition to the already daunting task to inhibit RAS 
activity in cancer. 
The current focus of RAS research has extended beyond oncogenic RAS isoforms to 
their wild-type counterparts. Accumulating evidence suggests a significant but complex role of 
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wild-type RAS isoforms in oncogenic RAS-driven tumorigenesis, an interaction network that 
appears to be highly context-dependent. Such studies largely fall into two broad categories: 1) 
studies of the wild-type counterpart of the oncogenic RAS isoforms, and 2) studies of the 
remaining two wild-type RAS isoforms in the presence of the oncogenic isoform.  
Bergo and colleagues used the Kras2LSLMx1-Cre (KM) mouse model to study KrasG12D-
induced leukemia, and found that all T-cell acute lymphoblastic leukemia (T-ALL) tumors in 
bone marrow-transplanted mice demonstrated loss of the wild-type Kras2 allele, suggesting a 
tumor suppressive role of wild-type KRAS in this model (Staffas et al., 2015). Similarly, Balmain 
and colleagues also reported tumor suppressive functions of HRASWT and KRASWT in 
experimental models of HRAS-driven non-melanoma skin cancer and KRAS-driven lung cancer, 
respectively (To et al., 2013). In delineating the effects of Kras copy number changes on tumor 
formation, a tumor suppressor effect of wild-type Kras was proposed for a carcinogen-induced 
mouse model of colorectal neoplasms, based on the observation that compared to wild-type 
(Kras+/+) mice, hemizygous Kras (Kras+/-) mice developed more and bigger colorectal tumors 
(Luo et al., 2014). Of note, this study was not investigating wild-type KRAS function in the 
presence of oncogenic KRAS. To determine the role of KRAS in regulating the tumor 
suppressor and RAS effector RASSF1A, Barbacid, Kolch and co-workers compared signaling of 
an isogenic cell line pair HCT-116 (KRASG13D/WT) and Hke3 (KRAS-/WT), and found that 
KRASG13D activates the proapoptotic MST2 pathway. By using siRNAs selectively targeting 
KRASWT, the authors determined that it antagonizes the activation of the MST2 pathway by 
mutant KRAS, and concluded that in colorectal cancer, wild-type KRAS supports mutant KRAS 
transformation (Matallanas et al., 2011). Therefore, the role of wild-type RAS in oncogenesis 
differs depending on the model system. 
Studies that primarily focused on studying wild-type RAS isoforms other than the wild-
type counterpart of oncogenic RAS began with a landmark study by the Counter laboratory, 
where they revealed a RASmut-PI3K-Akt-eNOS-RASWT activation mechanism in an HRASmut-
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expressing human kidney cell-derived cell line and in a panel of KRASmut human pancreatic 
ductal adenocarcinoma cell lines (Lim et al., 2008). In a similar vein, Jeng et al. proposed that 
allosteric stimulation of SOS by KRASmut activates RASWT (Jeng et al., 2012). KRASmut has been 
shown to depend on RASWT for activation of the G2 DNA damage checkpoint and timely 
progression through mitosis (Grabocka et al., 2014). Work by McCormick et al. also suggested 
the need for the other two RASWT isoforms for proliferation in a third isoform-mutated cancer cell 
line. In this study, oncogenic and wild-type RAS isoforms have reported to be responsible for 
regulating different aspects of signal transduction, with oncogenic RAS modulating basal 
mitogen-activated protein kinase (MAPK) pathway signaling, and WT isoforms controlling 
response to growth factor signaling (Young et al., 2013). However, in vivo studies by To et al. 
illustrated a more complex picture of wild-type RAS biology. While HRASWT suppressed 
KRASmut-driven lung carcinogenesis, KRASWT cooperated with HRASmut to drive the formation of 
skin papillomas (To et al., 2013). Intriguingly, NRASWT had opposing effects in different tumor 
types: it acted as a tumor suppressor in KRASmut lung tumors, but supported HRASmut-induced 
skin carcinogenesis (To et al., 2013). Hence, in either type of wild-type RAS study, the function 
of wild-type RAS in RAS-mutant cancers is not uniform, suggesting strong context dependency.  
 Surprisingly little is known about whether NRAS-mutant cancers require KRASWT or 
HRASWT for tumor initiation and/or maintenance. Given the fact that RAS isoforms themselves 
are distinct in their functions (Castellano and Santos, 2011; Newlaczyl et al., 2014), NRAS-
mutant diseases may have different functional requirements for the other two wild-type isoforms, 
and thus require independent investigation. 
 Although the majority of RAS-mutant cancers harbor KRAS mutations, NRAS mutations 
are highly enriched in certain types of cancers, such as melanoma, thyroid cancer, and acute 
myeloid leukemia (AML) (Cox et al., 2014). Melanoma is the deadliest form of skin cancer, and 
the sixth most common cancer in the United States. Mutations in NRAS arise in 28-30% of all 
melanoma patients, rendering them the second largest genetic subpopulation (Cancer Genome 
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Atlas, 2015). In addition, compared to patients with BRAF-mutant melanoma or without 
mutations in NRAS or BRAF, patients with NRAS-mutated melanoma have a worse prognosis 
(Jakob et al., 2012), and there are no FDA-approved targeted therapies for this disease, 
indicating a strong incentive for an in-depth molecular characterization of this subclass. 
Therefore, NRAS-mutant melanoma not only represents an excellent disease model to study 
the interplay of WT and oncogenic RAS, but also is in dire need of a deeper understanding of its 
biology to lay the foundation for identifying druggable targets. 
In the present study, I sought to determine the roles of wild-type (WT) RAS isoforms in 
NRAS-mutant melanoma. Cellular assays examining cell proliferation and clonogenic survival in 
both 2D and 3D culture revealed a need for both wild-type RAS isoforms (KRASWT and 
HRASWT) in all NRAS-mutant melanoma cells. To further understand the causes of cell death, I 
examined cell cycle distribution and Annexin V staining intensities of cells following KRASWT 
depletion, and showed that loss of KRASWT led to both G1 cell cycle arrest and apoptosis. To 
delineate the molecular underpinnings of these effects, I first employed a candidate approach, 
and examined one of the best-known regulators of cell cycle arrest and apoptosis, p53. I found 
that p53 protein stability and hence protein abundance was increased upon loss of KRAS, 
leading to an upregulation of many of its target genes. Contemporaneously, my collaborators 
also performed an unbiased reverse-phase protein array (RPPA) analysis to identify proteins 
that are selectively regulated in an isoform-specific manner. One such protein was ribosomal 
protein S6 (rpS6), a component of the 40S ribosomal subunit. Specifically, KRAS knockdown 
strongly suppressed phosphorylation of rpS6 at Ser235 and Ser236, which are substrates of 
S6K1. Dynamic dissection of rpS6 phosphorylation demonstrated the involvement of S6K1 but 
not ERK in phosphorylating rpS6 with or without depletion of KRASWT. Together, these findings 
unveil the dependence of NRAS-mutant melanoma on RASWT, and provide insight into the 
critical role of KRASWT in this disease. 
 
 65 
Methods and Materials 
Cell culture and reagents 
SK-MEL-147, SK-MEL-173, SK-MEL-119, SK-MEL-103, Mel224, Sbc12, and 293T cell 
lines were grown in DMEM-H (Gibco) supplemented with 10% FBS (HyCloneTM, Thermo 
Scientific) and 1% gentamycin/kanamycin (Tissue Culture Facility (TCF), Lineberger 
Comprehensive Cancer Center (LCCC), University of North Carolina at Chapel Hill (UNC-CH)). 
 
shRNA constructs 
Two hairpins sequence targeting (shNRAS-3 and shHRAS-3) were synthesized by 
Integrated DNA Technologies, and were cloned into a pLKO.1 puro vector (Addgene, #8453). 
The shRNA plasmids targeting p53 and the shNT plasmid were kind gifts from Dr. Yanping 
Zhang and Dr. Channing Der, respectively (UNC-Chapel Hill). All other shRNA constructs were 
purchased from the Lenti-shRNA Core Facility at UNC-Chapel Hill. Target sequences for all 
hairpins used in this study are summarized below. 
shRNA TRC Clone ID  Target Sequence 
shNT N/A CAACAAGATGAAGAGCACCAA 
shNRAS-1 TRCN0000033254 CGCACTGACAATCCAGCTAAT 
shNRAS-2 TRCN0000033258 CAAGAGTTACGGGATTCCATT 
shNRAS-3 N/A GTGCCATGAGAGACCAATACA 
shKRAS-1 TRCN0000010369 CAGTTGAGACCTTCTAATTGG 
shKRAS-2 TRCN0000033260 GAGGGCTTTCTTTGTGTATTT 
shHRAS-1 TRCN0000040089 AAGAGTGCGCTGACCATCCAC 
shHRAS-2 TRCN0000040091 GACGTGCCTGTTGGACATCCT 
shHRAS-3 N/A GAGTGGAGGATGCCTTCTACA	  
shp53-1 TRCN0000003753 CGGCGCACAGAGGAAGAGAAT 
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shp53-2 TRCN0000003755 GTCCAGATGAAGCTCCCAGAA 
shp53-3 TRCN0000003756 CACCATCCACTACAACTACAT 
shp53-4 TRCN0000003757 CTGTAGCCCATGTTGTAGCAA 
 
Lentivirus production and infection 
To produce lentivirus, 293T cells were transfected with pLKO.1 vector-based non-
targeting shRNA (shNT) or shRNA against a specific gene, in combination with psPAX2 and 
pMD2.G (packaging vectors), at a ratio of 4:3:1. After overnight transfection, the culture medium 
was changed to DMEM-H supplemented with 20% FBS. Thirty-six hours later, viral 
supernatants were harvested and filtered through a sterile 0.45 µm filter to remove cell debris. 
Cleared supernatants were aliquotted and frozen at -80°C until use. Cells were infected with an 
appropriate amount of virus in 5 µg/ml polybrene (Millipore) overnight. Selection of transduced 
cells in puromycin (1 µg/ml) was complete at 48 h after infection. 
 
Western blotting 
Cells were washed twice with ice-cold PBS and lysed in RIPA buffer (150 mM NaCl, 1% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0) containing 1X protease 
inhibitors (BaculoGoldTM Protease Inhibitor Cocktail, BD Biosciences, #51-21426Z) and 1× 
phosphatase inhibitors (HaltTM Phosphatase Inhibitor Cocktail, Thermo Scientific, #78420). 
Lysates were depleted of cell debris by centrifugation at maximum speed (4°C, 10 min), then 
proteins were quantified by Bradford assay (DCTM Protein Assay, Bio-Rad), normalized, 
reduced, denatured at 95°C for 5 min, and resolved by SDS gel electrophoresis. Proteins were 
transferred to PDVF membranes (Millipore, #IPFL00010) and probed with primary antibodies at 
4°C overnight. After incubation with the appropriate secondary anti-mouse (GE Healthcare, 
NA931V) or anti-rabbit (GE Healthcare, NA934V) antibody, proteins were detected by 
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chemiluminescence (Thermo Scientific, #34075). Below is a list of primary antibodies used in 
this study. 
Protein Manufacturer Catalog # 
ERK Cell Signaling Technology 9102 
p-ERK (T202/Y204) Cell Signaling Technology 4370 
MEK Cell Signaling Technology 4694 
p-MEK (Ser217/221) Cell Signaling Technology 9154 
RSK Cell Signaling Technology 9355 
p-RSK (T259/S263) Cell Signaling Technology 9344 
Akt Cell Signaling Technology 9272 
p-Akt (Ser473) Cell Signaling Technology 9271 
p-Akt (Thr308) Cell Signaling Technology 9275 
mTOR Cell Signaling Technology 2972 
p-mTOR (S2448) Cell Signaling Technology 5536 
S6K1/p70 S6K Cell Signaling Technology 9202 
p-S6K1 (T389) Cell Signaling Technology 9205 
ribosomal protein S6 (rpS6) Cell Signaling Technology 2217 
p-rpS6 (S235/236) Cell Signaling Technology 2211 
p-rpS6 (S240/244) Cell Signaling Technology 2215 
β-actin Sigma-Aldrich A5316 
NRAS (F155) Santa Cruz Biotechnology sc-31 
KRAS Calbiochem OP-24 
HRAS (C-20) Santa Cruz Biotechnology sc-520 
PUMA (H-136) Santa Cruz Biotechnology sc-28226 
p21 Santa Cruz Biotechnology sc-397 
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p53 (DO-1) Santa Cruz Biotechnology sc-126 
cyclinD1 Cell Signaling Technology 2922 
Bax BD Biosciences 554104 
p73 Santa Cruz Biotechnology sc-7957 
FoxO3a Bethyl Laboratories A300-453A-T 
 
RNA isolation, reverse transcription and real-time qPCR 
Total RNA was isolated using a QIAshredderTM homogenizer (Qiagen, #79654) and an 
RNeasy® Mini Kit (Qiagen, #74104). Reverse transcription was performed using the High 
Capacity RNA-to-cDNA kit (Thermo Fisher Scientific, #4387406). Samples were prepared using 
the TaqMan Gene Expression Master Mix (Thermo Fisher Scientific, #4369016) and real-time 
quantitative Taqman PCR was performed on the QuantStudio 6 Flex (Thermo Fisher Scientific) 
with FAM/MGB labeled probes against NRAS (Hs00180035_m1), KRAS (Hs00364284_g1), 
HRAS (Hs00978050_g1), or PUMA/BBC3 (Hs00248075_m1), normalized to a human ACTB (β-
actin) endogenous control (Thermo Fisher Scientific, #4310881E). 
 
MTT proliferation assay 
Cells were plated at 1-2 X103 cells per well in 96-well plates, and stained with 5 mg/ml 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich M5655) the next 
day (day 1), and then either on days 3, 5, and 7 or on days 4, 7, and 10, depending on the 
proliferation rate of each cell line. Formazan products were solubilized using acidified 
isopropanol (0.04N HCl in isopropanol), and absorbance was measured at 570 nm, with 
background subtraction at 650 nm. Absorbance was normalized to the average value for day 1 
and growth curves were generated from the average of all experiments. 
 
 
 69 
2D clonogenic assay 
Clonogenic assays were performed as described previously (Franken et al., 2006) with 
minor modifications. Briefly, cells were plated in triplicate wells at 500 - 1000 cells/well in 6-well 
plates, and incubated at 37°C for 2 weeks. After removal of culture medium, cells were fixed 
and stained with a crystal violet staining solution (0.5% crystal violet, 50% methanol, 10% acetic 
acid) at room temperature for 30 min. The stain was decanted, and plates were carefully rinsed 
with distilled water until background staining of the wells was minimized. Colonies were imaged, 
and then quantified with ImageJ 1.45s. 
 
Soft agar assay 
Anchorage-independent growth was measured as described previously (Alan et al., 
2010). Single-cell suspensions of cells (1 X 104 cells per well in 6-well plates) were suspended 
in 0.4% agar (BD Biosciences) in complete medium and layered on top of 0.6% agar. After 2-4 
weeks, colonies were stained with 2 mg/ml MTT, and colony numbers were quantified with 
ImageJ 1.45s. 
 
Cell cycle analysis 
Samples were prepared according to the manufacturer’s protocol (Roche, 
#11348639001) with slight modifications. Briefly, ~1 X 106 cells were dissociated with TrypLETM 
Express (ThermoFisher Scientific), washed twice with cold phosphate-buffered saline (PBS), 
fixed with 70% ice-cold ethanol, and stored at -20°C until use. Fixed cells were washed again 
with cold PBS, stained with 1 ml of propidium iodide staining solution (0.02 mg/ml propidium 
iodide, 0.2 mg/ml RNase A) per condition, and incubated at 4°C overnight. Cells were filtered 
through 30 µm CellTrics® filters prior to analysis. Measurement of cell cycle distribution was 
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performed on a Beckman Coulter CyAn ADP flow cytometer (Flow Cytometry Core Facility, 
UNC-Chapel Hill), and analyzed using ModFit Software (Verity Software House). 
 
Annexin-V/PI staining 
Cells were collected and stained using the Annexin-V-FLUOS Staining Kit (Roche, 
#11858777001). In brief, ~1 X 106 cells were washed with PBS, spun down at 200 X g for 5 min, 
resuspended in 100 µl of Annexin-V-FLUOS labeling solution, and incubated at room 
temperature for 15 min. Fluorescence was then analyzed by a Beckman Coulter CyAn ADP flow 
cytometer (Flow Cytometry Core Facility, UNC-Chapel Hill). 
 
Reverse-phase protein array analysis 
Reverse-phase protein array (RPPA) analysis was performed as described previously 
(Federici et al., 2013). Briefly, samples from the triplicate sets of five melanoma cell lines (SK-
MEL-147, SK-MEL-173, SK-MEL-119, Mel224, and SK-MEL-103) were printed in triplicate spots 
on nitrocellulose-coated glass slides (GRACE Bio-Labs) using an Aushon 2470 arrayer 
equipped with 185 µm pins (Aushon Biosystems), according to the manufacturer's instructions. 
Reference standard lysates, composed of HeLa + pervanadate (BD), Jurkat + etoposide (Cell 
Signaling), and Jurkat + calyculin A (Cell Signaling) cell lysates, were printed in 10-point dilution 
curves as procedural controls and as positive controls for antibody staining. Each reference 
standard curve was printed in triplicate at concentrations of 0.5 µg/µl and 0.125 µg/µl. A 
selected subset of the printed array slides was stained with SYPRO Ruby Protein Blot Stain 
(Invitrogen) to estimate sample total protein concentration, and the remaining slides were stored 
desiccated at −20°C. Just before antibody staining, printed slides were treated with 1× ReBlot 
Mild Solution (Chemicon) for 15 minutes, washed 2 times for 5 minutes with PBS (Invitrogen), 
and incubated for 1 hour in blocking solution (2% I-Block (Applied Biosystems), 0.1% Tween-20 
in PBS). Immunostaining was completed on an automated slide stainer using a catalyzed signal 
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amplification kit (DAKO). The arrays were probed with a library of almost 200 antibodies against 
total, cleaved, and phosphoprotein endpoints. Primary antibody binding was detected using a 
biotinylated goat anti-rabbit immunoglobulin G (IgG) H+L (1:7500; Vector Laboratories) or rabbit 
anti-mouse IgG (1:10; DAKO) followed by streptavidin-conjugated IRDye680 fluorophore (LI-
COR Biosciences). Before use, primary antibodies were extensively validated for single-band 
specificity by Western immunoblotting with complex cellular lysates. Negative control slides 
were incubated with secondary antibody only. All SYPRO- and immuno-stained slides were 
scanned using a Revolution 4550 scanner (Vidar Corp.), and acquired images were analyzed 
with MicroVigene v4.0.0.0 (VigeneTech), which conducted spot detection, local background 
subtraction, negative control subtraction, replicate averaging, and total protein normalization, 
producing a single value for each sample. Unsupervised hierarchical clustering was conducted 
with JMP v5.1 (SAS Institute). Endpoint relative intensity correlation plots were conducted with 
GraphPad Prism v5 (GraphPad Software Inc.). 
 
Results 
KRASWT is essential for cell survival and proliferation in NRAS-mutant melanoma cells 
Previous studies in KRAS-mutant cancers have identified both tumor-promoting and 
tumor-suppressing roles of wild-RAS isoforms (Grabocka et al., 2014; Jeng et al., 2012; Lim et 
al., 2008; To et al., 2013; Weyandt et al., 2015; Young et al., 2013); NRAS-mutant cancers have 
not been evaluated. Therefore, I first tested whether wild-type KRAS (KRASWT) was necessary 
for cell proliferation in a panel of NRAS-mutant melanoma cells. I used a non-targeting (NT) 
shRNA and two independent short hairpins targeting NRAS, KRAS, or HRAS to selectively 
knock down each isoform. Knockdown efficiency was confirmed at both the mRNA level and 
protein level (Figure 3.1A,B). In all cell lines tested, KRAS depletion significantly impeded cell 
proliferation (Figure 3.1C). I also observed similar effects on cell proliferation upon HRAS 
depletion (data not shown). Additionally, KRAS knockdown strongly inhibited 2D clonogenic 
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growth (Figure 3.1D), as well as 3D anchorage-independent growth of NRAS-mutant cells 
(Figure 3.1E), indicating a loss of the transformed phenotype. Similar phenotypes were 
observed with HRAS depletion (Figure 3.5). Next, I determined whether cell cycle arrest and/or 
apoptosis could explain the reduced cell survival and proliferation. Propidium iodide (PI) staining 
revealed a marked increase in the G1 phase of the cell cycle (Figure 3.1F) upon KRAS 
knockdown, suggesting a G1 cell cycle arrest. In addition, KRAS silencing greatly increased the 
proportion of cells that were Annexin V(+)/PI(-), indicating induction of apoptosis. Together, 
these results show that KRASWT is essential for cell proliferation, survival and the transformed 
phenotype of NRAS-mutant melanoma cells, and that its loss results in cell cycle arrest and 
apoptosis. 
 
RAS isoforms play divergent roles in NRAS-mutant melanoma 
Earlier reports had not explicitly distinguished between the WT RAS isoforms (i.e., 
NRASWT and HRASWT) in KRAS-mutant cells. However, given that RAS isoforms exhibit 
different biological activities in various contexts (Fotiadou et al., 2007; Haigis et al., 2008; Parikh 
et al., 2007; Whitwam et al., 2007), by means of distinct effector utilization, I postulated that they 
perform different roles in NRAS-mutant cancer. In the present study, I asked whether the wild-
type isoforms (i.e., KRASWT and HRASWT) have different biological functions in NRAS-mutant 
melanoma cells. First, I observed changes in cellular morphology, and surprisingly, found 
distinct morphologies upon knockdown of each RAS isoform:  cells with KRAS knockdown 
appeared highly rounded and refractile, consistent with the early stages of apoptotic death. In 
contrast, NRAS depletion gave rise to a flattened morphology, whereas HRAS knockdown led to 
an elongated, fibroblastic appearance (Figure 3.2A). These distinct morphological 
consequences imply distinct consequences of the knockdown of each isoform on effector 
utilization, resulting in different signaling outcomes. I therefore examined activation of the RAF-
MEK-ERK and AKT-mTOR-S6 pathways, two of the best-studied canonical effector pathways of 
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RAS proteins. As predicted by the different morphological consequences, loss of the three RAS 
isoforms resulted in different consequences to these effector pathways (Figure 3.2B). In SK-
MEL-147 cells, NRAS knockdown resulted in mild loss of both total and phosphorylated MEK, 
ERK, and RSK, whereas KRAS depletion elevated phosphorylation of those proteins without 
affecting their total protein levels. HRAS silencing had no effect on MEK or ERK signaling, but 
suppressed RSK phosphorylation. In SK-MEL-147 (Figure 3.2B) and three other NRAS-mutant 
cell lines (SK-MEL-119, SK-MEL-173 and Sbc12; Figure 3.6B), knockdown of NRAS 
consistently reduced phosphorylation of ERK, whereas knockdown of KRAS increased it, and 
knockdown of HRAS had little effect. In contrast, although phosphorylation of AKT at S473 was 
diminished in SK-MEL-147 cells (Figure 3.2B), AKT phosphorylation did not exhibit a consistent 
alteration across the cell lines (Figure 3.6B). Overall, these observations indicate that RAS 
isoforms are not redundant, and have at least some functionally distinct roles, despite their high 
degree of sequence identity and a shared signaling network. Additionally, the finding that 
alterations in phosphorylation of ERK but not AKT were consistent across the cell lines upon 
knockdown of each RAS isoform implies that RAS isoforms may control the RAF-MEK-ERK 
pathway more tightly than the PI3K-AKT-mTOR-S6 pathway in NRAS-mutant melanoma.  
Interestingly, although phosphorylation of both AKT and rpS6 was reduced in SK-MEL-147 
cells, phosphorylation of mTOR was if anything elevated (Figure 3.2B).  This suggests that 
regulation of rpS6 may be more complex than currently described. 
 
KRAS depletion increases p53 stability 
The observation that KRASWT depletion resulted in both G1 cell cycle arrest and 
apoptotic cell death implied possible impact on a master regulator of cell survival. To test this 
hypothesis, I examined the expression of p53, the guardian of the genome (Lane, 1992), and a 
known regulator of both cell cycle progression and apoptosis (Chen, 2016), in cells with KRAS 
knockdown. As anticipated, KRAS silencing with shKRAS-1 and shKRAS-2 increased levels of 
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p53 protein by 4.5- and 7.4-fold, respectively (Figure 3.3A). Accordingly, well-known p53 target 
genes, such as Mdm2, p21 and PUMA were also elevated at the protein level (Figure 3.3B). 
PUMA, a potent killer (Yu and Zhang, 2003, 2008), was also strongly upregulated at the mRNA 
level in both SK-MEL-147 (Figure 3.7) and other NRAS-mutant melanoma cell lines (data not 
shown). Since p53 is not usually regulated at the transcriptional level (Meek, 2015), I tested 
whether increased protein stability was the cause of p53 upregulation. Indeed, by using 
cycloheximide to inhibit de novo protein synthesis, I observed that the half-life of p53 protein 
increased 2.3-fold upon KRAS knockdown (Figure 3.3C). These data demonstrate that NRAS-
mutant melanoma cells respond to KRASWT loss by upregulating p53, indicating a stress 
response. Whether the observed increases in cell cycle arrest and/or apoptosis are dependent 
on this upregulation of p53 remain to be determined. 
  
KRAS depletion impairs phosphorylation of ribosomal protein S6 
To obtain a more global view of the signaling outcomes upon knockdown of each RAS 
isoform, my collaborators Emanuel F. Petricoin III and Mariaelena Pierobon performed reverse 
phase protein array (RPPA) analysis (Federici et al., 2013) on my cell lysates to detect the 
activation state of nearly 200 proteins in a high-throughput manner. Using RPPA, we observed 
an unexpectedly strong correlation between knockdown of KRAS and low-level phosphorylation 
of the ribosomal protein rpS6 at residues S235/236 (Figure 3.4A). I then validated this 
decreased phosphorylation by western blotting of additional cell lysates (Figure 3.4B).  
 Phosphorylation of rpS6 downstream of RAS is typically thought to result from activity of 
the AKT-mTOR-S6K1-S6 signaling pathway.  Yet in these NRAS-mutant melanoma cell lines, 
although loss of KRAS was strongly correlated with reduced phosphorylation of rpS6 (Figure 
3.4A,B), it was not strongly correlated with reduced phosphorylation of AKT (Figure 3.6B).  
Although rpS6 can also be activated downstream of RAF-MEK-ERK-RSK, in these cells, loss of 
KRAS elevated phospho-ERK and phospho-RSK (Figures 3.2, 3.6B) rather than reduced them.  
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One possible explanation for these results could be an indirect effect on other kinases that can 
phosphorylate rpS6 at S235/236.  Serine residues 235 and 236 are two of five serines at the C-
terminus of rpS6 that become phosphorylated in response to multiple physiological, pathological 
and pharmacological stimuli (Meyuhas, 2008). All five of these serines (S235, S236, S240, 
S244, S247) are substrates for S6K1 (Ballou et al., 1991; Chung et al., 1992), whereas both 
p90RSK (Pende et al., 2004; Roux et al., 2007) and PKA (Moore et al., 2009) can also 
phosphorylate S235 and S236.  In contrast, CK1 exhibits specificity towards S247 (Hutchinson 
et al., 2011). To determine the major kinase responsible for phosphorylating S235/236 in NRAS-
mutant melanoma cells, I examined the kinetics of rpS6 phosphorylation at both S235/236 and 
S240/244 in the presence or absence of KRASWT depletion. In cells treated with non-targeting 
shRNA, rpS6 phosphorylation at both S235/236 and S240/244 increased gradually over 60 min 
(Figure 3.4C). As expected, phosphorylation of rpS6 at the S6K1-only sites of S240/244 tracked 
closely with S6K1 activation, as measured by S6K1 phosphorylation at T389. Importantly, rpS6 
phosphorylation at S235/236 also followed the same trend. In contrast, the signal amplitudes of 
ERK phosphorylation in KRAS-depleted cells were higher at all time points, and followed 
different kinetics. These observations indicate that rpS6 phosphorylation in this system is largely 
regulated by S6K1, and not the ERK pathway. Notably, phosphorylation of both S6K1 and rpS6 
was much less robust and peaked earlier (at 30 min) in cells treated with shRNA directed 
against KRAS (Figure 3.4E), indicating reduced activation and enhanced deactivation of this 
pathway upon depletion of KRASWT. These findings, together with the observations of a variable 
AKT response (Figure 3.6B) suggest that, in NRAS-mutant melanoma, KRAS may bypass AKT-
mTOR to more directly control S6K1 and thus rpS6 activity.  
 I next asked whether this phenotype is unique to NRAS-mutant melanoma. To this end, I 
measured rpS6 phosphorylation upon RAS isoform knockdown in a panel of five non-small cell 
lung cancer cell lines (H2228, H358, H441, H23, H1299), and found that all five showed a 
striking loss of phosphorylation at S235 and S236 upon depletion of KRAS, but not NRAS or 
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HRAS (Figure 3.8A). Of note, H358, H441 and H23 all harbor a KRASG12 mutation, H1299 
harbors an NRASQ61K mutation, and H2228 does not have a RAS mutation. These results 
demonstrate that the loss of rpS6 phosphorylation at S235/236 is independent of both tissue of 
origin and RAS mutation status.  
Several studies have shown that rpS6 gene dosage is closely linked to p53 activation 
(Fumagalli et al., 2009; McGowan et al., 2011; Panic et al., 2007; Panic et al., 2006; Sulic et al., 
2005). Further, a pancreatic cancer study used rpS6P−/− mice (lacking all five phosphorylatable 
sites in rpS6) to demonstrate the effect of rpS6 phosphorylation on tumor development, and 
found that those mice had increased p53 tissue staining (Khalaileh et al., 2013). Therefore, to 
understand whether the increased levels of p53 that I observed upon depletion of KRASWT 
(Figure 3.3) were due to impaired rpS6 phosphorylation, I treated cells with rapamycin, and 
found that, while rpS6 phosphorylation quickly declined to an undetectable level, p53 remained 
steady until 24 h after treatment (Figure 3.8B), indicating that the increase in p53 and 
suppression of rpS6 phosphorylation lie in two independent pathways. Overall, my findings 
uncover a critical role of KRASWT in NRAS-mutant melanoma, loss of which leads to 
upregulation of p53 and its target genes, and, in a parallel fashion, to severe impairment of rpS6 
phosphorylation that is S6K1-dependent but AKT-mTOR-independent. 
 
Discussion 
The roles of wild-type RAS isoforms in RAS-mutant cancers re-entered the spotlight 
when several groups demonstrated that they play important roles in RAS-mutant cancers 
(Grabocka et al., 2014; Jeng et al., 2012; Lim et al., 2008; To et al., 2013; Weyandt et al., 2015; 
Young et al., 2013). Although the majority of studies in KRAS-mutant cancers described a need 
for wild-type HRAS and/or NRAS in tumor initiation and/or progression (Grabocka et al., 2014; 
Lim et al., 2008; Young et al., 2013), those observations cannot simply be generalized to other 
cancer types and different oncogenic RAS isoforms, given the highly complex and context-
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dependent nature of interactions between wild-type and oncogenic forms of different RAS family 
members. In this study, I investigated the roles of wild-type RAS in NRAS-mutant melanoma, 
with a special focus on KRASWT, and show here that it is critical not only in maintaining the 
transformed phenotype, but also in fundamental cellular processes such as proliferation and 
survival. Furthermore, I provide evidence that the biological functions of the wild-type RAS 
isoforms are not identical, different from findings that suggested that the wild-type RAS proteins 
are functionally redundant (Grabocka et al., 2014; Jeng et al., 2012; Young et al., 2013). 
Specifically, these studies showed that the two wild-type RAS isoforms responded the same 
way both phenotypically and mechanistically. Discrepancies among studies are very likely due 
to the specific disease model, and the specific RAS isoform that drives the disease. In fact, I 
noticed that knockdown of NRAS and HRAS behave more similarly to one another than 
knockdown of KRAS. For example, KRAS depletion resulted in cell death more rapidly than 
NRAS or HRAS depletion, based on cellular morphology. The highly rounded, refractile 
phenotype shown in Figure 3.2A may reflect the initiation of cellular death. Furthermore, NRAS 
and HRAS also more mirror each other in terms of modulation of downstream signaling (Figure 
3.2B, Figure 3.7 and Figure 3.4A-C). It is therefore not entirely surprising that studies in KRAS-
mutant cancers all show similar effects of knocking down either NRAS or HRAS. In addition, 
such differences in conclusions also heavily rely on the exact definition of “functional 
redundancy”. It is known that there is functional overlap (Johnson et al., 1997) and difference 
(Fotiadou et al., 2007) among the RAS isoforms. Thus, depending on the specific biological 
endpoint examined, there may or may not be a distinction between the two wild-type RAS 
proteins. 
Our findings are also in line with previous observations that demonstrated a potential 
need for wild-type RAS in NRAS-mutant cells. Cell proliferation defect of the RD 
rhabdomyosarcoma cell line (NRASQ61H) was observed upon knockdown of HRASWT and/or 
KRASWT(Young et al., 2013). In the SK-MEL-103 (NRASQ61L) melanoma cell line, knockdown of 
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HRASWT was shown to enhance γH2AX levels, indicating DNA damage regulation by HRASWT 
(Grabocka et al., 2014). 
Another interesting observation is the upregulation of p53 protein expression upon 
KRAS knockdown in some NRAS-mutant cell lines. Using cycloheximide to block de novo 
protein synthesis, I showed that p53 protein was stabilized, and its half-life increased more than 
2-fold. Melanoma is different from many other cancers in that it has a relatively low frequency of 
TP53 mutation (19%) (Petitjean et al., 2007; Vultur and Herlyn, 2013). Indeed, all cell lines used 
in my study are TP53WT. The increase in p53 protein may not be a direct consequence of KRAS 
knockdown, and may instead indicate a more general stress response of the cells when KRAS 
is depleted. A wide range of cellular stresses induce p53, including DNA damage, oncogene 
activation, ribosomal stress, etc. (Colman et al., 2000; Haupt, 2004; Meek, 2015; Xu, 2003). In 
my system, I did not observe significant DNA damage as measured by γH2AX staining, nor did I 
observe induction of Ser15 phosphorylation upon treatment with shKRAS-1, which is indicative 
of DNA-damage (Shieh et al., 1997) (data not shown). No changes in ribosomal proteins L5, 
L11, or L23 were detected (data not shown), indicating a lack of ribosomal stress (Deisenroth 
and Zhang, 2010). Therefore, it remains unclear how KRAS depletion leads to accumulation. 
Noteworthy to mention, although I observed increased stabilization of p53 protein, I 
counterintuitively found enhanced Mdm2 interaction with p53 and increased ubiquitination of 
p53 upon treatment with shKRAS-2 (data not shown). These findings suggest an 
unconventional means of p53 protein induction. Future studies are necessary to elucidate the 
precise mechanism of p53 stabilization upon KRAS depletion.  
 Using an unbiased approach, we identified a novel link between KRAS and ribosomal 
protein S6 (rpS6) phosphorylation state. In all cell lines tested for validation, knockdown of 
KRAS resulted in the strongest suppression of rpS6 phosphorylation at Ser235 and Ser236. 
rpS6 is one of the 33 proteins that constitute the 40S small subunit of eukaryotic ribosomes. It 
has been more thoroughly studied than many other ribosomal proteins because it was the first 
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one shown to undergo inducible phosphorylation (Meyuhas, 2015). As a ribosomal protein, 
phosphorylated rpS6 has been assumed to exert significant impact on global protein synthesis. 
However, contradictory to this postulation, several studies demonstrated that rpS6 
phosphorylation apparently lacks an important role in global protein synthesis (Garelick et al., 
2013; Johnson and Warner, 1987; Ruvinsky et al., 2005). Similarly, genetic studies deleting its 
upstream kinases, S6K1 and S6K2 (Chauvin et al., 2014; Mieulet et al., 2007), also reported no 
effect on global protein synthesis. Other physiological roles of rpS6 phosphorylation include 
regulation of cell size, normal muscle function, hypertrophic responses, cell proliferation, 
clearance of apoptotic cells, and tumorigenicity (Meyuhas, 2015). Thus, the functional outcome 
of KRAS-knockdown-induced rpS6 hypophosphorylation warrants further detailed analysis. 
Overall, this isoform-selective control of downstream signaling events may offer mechanistic 
insights into isoform-related phenotypes. 
 However, contrary to the common perception that rpS6 phosphorylation serves a reliable 
marker of mTOR pathway activity (Andreoli et al., 2015; Iwenofu et al., 2008), I show that, in the 
context of KRAS depletion, rpS6 phosphorylation is suppressed regardless of AKT or mTOR 
activity, but its phosphorylation kinetics still followed that of S6K1. One possible explanation is 
that KRAS utilizes a bypass route to directly modulate S6K1 activity. Aside from phosphorylation 
by mTORC1 at Thr389 (Jacinto et al., 2004; Kim et al., 2003), S6K is also directly 
phosphorylated by PDK1 at Thr229 (Alessi et al., 1998; Pullen et al., 1998). It is therefore 
possible that KRAS regulates the ability of PDK1 to phosphorylate S6K1. KRAS-specific 
regulation of PP1, the only known phosphatase responsible for dephosphorylating rpS6, may 
also play a role in dictating its final phosphorylation state. 
 In summary, I show dependence of NRAS-mutant melanoma cells on wild-type KRAS 
for survival, proliferation and a transformed phenotype. While both wild-type HRAS and wild-
type KRAS are needed for these cellular processes, they exhibit distinct impacts on cellular 
morphology and canonical effector pathway signaling. Importantly, I uncover a novel link 
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between KRAS and rpS6 that neither NRAS nor HRAS shares. Future work investigating both 
regulation and functional consequences of impaired rpS6 phosphorylation may shed light on the 
unique function of KRASWT in NRAS-mutant melanoma.  
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Figure 3.1. KRASWT is essential for cell proliferation and survival in NRAS-mutant 
melanoma cells. 
A. Western blots of NRAS, KRAS, and HRAS protein expression upon shRNA knockdown. SK-
MEL-147 cells were infected with lentivirus expressing short-hairpins against each of the RAS 
isoforms. Protein was harvested 48 h post puromycin selection. Beta-actin was used as a 
loading control. 
B. Real-time qPCR of NRAS, KRAS, and HRAS mRNA expression upon shRNA knockdown. 
SK-MEL-147 cells were infected with lentivirus expressing short-hairpins against each of the 
RAS isoforms. Total RNA was harvested 48 h post puromycin selection. Beta-actin was used as 
an internal control. 
C. MTT proliferation curves of a panel of NRAS-mutant melanoma cells (SK-MEL-147, SK-MEL-
103, Mel224, SK-MEL-173, SK-MEL-119, and Sbc12) with (shNT) or without KRASWT 
(shKRAS).  
D. 2D clonogenic growth of SK-MEL-147 with (shNT) or without KRASWT (shKRAS). Colonies 
were stained with a 0.5% crystal violet stain, and quantified by ImageJ. *** p < 0.0005. 
E. Anchorage-independent growth of of SK-MEL-147 with (shNT) or without KRASWT (shKRAS). 
Colonies were stained with 2mg/ml MTT, and quantified by ImageJ. ** p < 0.005. 
F. Propidium iodide staining of fixed SK-MEL-147 cells to determine cell cycle distribution 
following KRAS depletion. ** p < 0.001; *** p < 0.0001. 
G. Annexin V/propidium iodide staining of SK-MEL-147 cells following KRAS depletion. 
  
 82 
 
Figure 3.2. RAS isoforms perform divergent functions in NRAS-mutant melanoma cells. 
A. Microscopic images (4X magnification) of SK-MEL-147 cells treated with either a non-
targeting (shNT) shRNA or shRNA targeting each of the RAS isoforms. 
B. Western blot analysis of canonical downstream signaling pathway activities of RAS (RAF-
MEK-ERK-RSK and PI3K-AKT-mTOR-S6). 
  
 83 
 
Figure 3.3. KRAS depletion increases p53 protein stability and activation of its target 
genes. 
Western blot of p53 (A) and its target genes Mdm2, PUMA, and p21 (B) following KRAS 
depletion by shRNA in SK-MEL-147. 
C. To determine the half-life (t1/2) of p53 protein in SK-MEL-147 cells, 50 µg/ml cycloheximide 
(CHX) was added to cells, and protein was harvested at the indicated times. T1/2 was calculated 
using one-phase decay analysis in Prism 6. 
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Figure 3.4. KRAS, but not NRAS or HRAS depletion leads to severe impairment of rpS6 
phosphorylation at Ser235/236. 
A. Endpoint relative intensity correlation plots of phosphorylation of Ser235/236 of ribosomal 
protein S6 based on RPPA analysis. Beta-actin was used as a loading control. 
B. Western blots of phosphorylated rpS6 (S235/236) in multiple NRAS-mutant cell lines. Total 
ERK or beta-actin was used as a loading control. 
C. SK-MEL-147 cells with or without KRAS knockdown were serum-starved for 18 h and 
stimulated with 10% FBS for the indicated times. Phosphorylation of rpS6 (S235/236 and 
S240/244), S6K1 (T389) and ERK (T202/Y204) was monitored over time. Graphs represent 
signal intensities of phosphorylated proteins normalized to their total counterpart from three 
independent experiments. 
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Figure 3.5. HRASWT is essential for cell proliferation, survival and transformed growth in 
NRAS-mutant melanoma cell lines. 
A. MTT proliferation curves of a panel of NRAS-mutant melanoma cells (SK-MEL-147, SK-MEL-
103, Mel224, SK-MEL-173, SK-MEL-119, and Sbc12) with (shNT) or without HRASWT 
(shHRAS). Growth curves for NT cells are identical to those shown in Fig. 1B, because all 
knockdowns were evaluated in the same set of experiments. 
B. 2D clonogenic growth of SK-MEL-147 with (shNT) or without HRASWT (shHRAS). Colonies 
were stained with a 0.5% crystal violet stain, and quantified by ImageJ. *** p < 0.0005. 
C. Anchorage-independent growth of of SK-MEL-147 with (shNT) or without HRASWT 
(shHRAS). Colonies were stained with 2mg/ml MTT, and quantified by ImageJ. ** p < 0.005. 
  
 86 
 
Figure 3.6. RAS isoforms differentially regulate cell morphology and downstream 
signaling. 
A. Microscopic images (4X magnification) of NRAS-mutant melanoma cells treated with either a 
non-targeting (shNT) shRNA or shRNA targeting each of the RAS isoforms. 
B. Western blot analysis of AKT and ERK phosphorylation upon RAS isoform knockdown in 
NRAS-mutant melanoma cells. 
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Figure 3.7. KRASWT depletion specifically upregulates PUMA mRNA. 
Real-time qPCR of PUMA mRNA expression upon shRNA knockdown of each RAS isoform. 
SK-MEL-147 cells were infected with lentivirus expressing short-hairpins against each of the 
RAS isoforms. Total RNA was harvested 48 h post puromycin selection. Beta-actin was used as 
an internal control. 
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Figure 3.8. rpS6 phosphorylation is decreased upon KRAS depletion in NSCLC cells and 
does not cause p53 protein upregulation. 
A. Western blot analysis of rpS6 phosphorylation at S235/236 in non-small cell lung cancer cell 
lines. 
B. To determine whether p53 increases as a result of suppressed rpS6 phosphorylation at 
S235/236, 100 nM rapamycin was added to SK-MEL-147 culture, and cell lysates were 
harvested at indicated times for western blot analysis. 
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CHAPTER IV: CONCLUSIONS AND FUTURE DIRECTIONS 
 
Summary and Conclusions 
Situated at the center of a vast signaling network, RAS, an oncogene found in almost a 
third of human cancers, poses several major challenges to researchers investigating both RAS 
biology and RAS therapeutic targeting: exponentially increasing complexities due to the 
existence of multiple RAS isoforms and post-translational modifications; incomplete 
understanding of the interactions and relative significance of its many downstream effector 
pathways; the difficulty of targeting RAS directly; and clinical resistance to existing and 
upcoming targeted therapies directed against RAS effector pathways. My studies described 
herein addresses two aspects of these challenges. The first study uncovers a novel mechanism 
of resistance to inhibitors of the RAF-MEK-ERK kinase cascade in BRAF-mutant melanoma. 
The second study demonstrates the importance of WT RAS isoforms, especially KRASWT, in 
NRAS-mutant melanoma. 
Melanoma presents an excellent disease model for the study of RAS-directed drug 
resistance, not least in part because four out of seven approved RAS effector pathway inhibitors 
are approved for melanoma patients, and therefore the vast majority of clinical inhibitor 
resistance data have been obtained from treated melanomas. Identified mechanisms of 
resistance largely fall into two categories (Lito et al., 2013): activation of RAS-RAF-MEK-ERK 
pathway components that result in ERK reactivation (e.g., RAS or MEK mutations, BRAF 
alternative splicing, BRAF amplification, increased expression of CRAF or COT, etc.) or 
diminution of cell dependence on ERK signaling (e.g., PTEN and RB1 loss, activation of RTKs, 
etc.). In my study, I identified an atypical mechanism that does not directly belong to either of 
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these two classes. My findings show that overexpression of either the wild-type or a kinase-
inactive mutant form of the catalytic subunit of protein kinase CK2 (CK2α) promotes resistance 
to BRAF and MEK inhibitors, but can be reverted by an ATP-competitive ERK inhibitor, 
SCH772984. My observations were surprising in two ways. First, although CK2α promotes ERK 
reactivation, it is not an integral component of the RAS-RAF-MEK-ERK pathway. Hence, the 
exact mechanism of this enhanced ERK activity needs to be defined, but can be promiscuous 
owing to the huge repertoire of CK2α substrates. Secondly, all reported biological activities of 
CK2α to date are attributed to its kinase activity. However, my results indicate that the kinase 
function of CK2α is not required for promoting resistance. The only study, to my knowledge, that 
has linked CKα to scaffolding also suggested a contribution of its kinase function (Ritt et al., 
2007). Collectively, my findings provide insight into possibly neglected roles of CK2 in 
modulating the RAS-RAF-MEK-ERK pathway.  
Another area that has attracted much attention in the past several years is dissection of 
the roles of wild-type RAS isoforms in the presence of oncogenic RAS (Grabocka et al., 2014; 
Jeng et al., 2012; Lim et al., 2008; To et al., 2013; Weyandt et al., 2015; Young et al., 2013). As 
part of my doctoral work, I interrogated the roles of wild-type RAS, especially wild-type KRAS, in 
NRAS-mutant melanoma. Based on my data, I conclude that KRASWT plays a significant role in 
the maintenance of the transforming capabilities, as well as in cell proliferation and survival, of 
NRAS-mutant melanoma. I also demonstrate divergent contributions of RAS isoforms to cellular 
morphology and to canonical pathway signaling. Furthermore, KRAS depletion induces p53 
stabilization and concomitant increases in p21and PUMA, which are known to be key mediators 
of p53-induced G1 cell cycle arrest (Waldman et al., 1995) and apoptosis (Yu and Zhang, 
2003), respectively. Unbiased analysis of protein activation states following RAS isoform 
knockdown by reverse phase protein array (RPPA) unexpectedly revealed that rpS6 
phosphorylation is selectively impaired in KRAS-depleted cells. Intriguingly, rpS6 
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phosphorylation at S235/236 in KRAS-depleted cells does not correlate with AKT-mTOR activity 
or ERK-RSK signaling, implying a more direct means of controlling S6K1 signaling. These data 
provide evidence for a previously unappreciated role of RAS isoform-specific regulation of rpS6 
phosphorylation in NRAS-mutant cancer. Taken together, my work, for the first time to my 
knowledge, illustrates the dependence of an NRAS-mutant cancer on wild-type RAS isoforms, 
and particularly on wild-type KRAS.  
 
Future Directions 
Is CK2α-mediated resistance to RAF/MEK inhibition clinically relevant? 
My work shows the sufficiency of CK2α to promote resistance to BRAF and MEK 
inhibitors in melanoma cells through regulating the RAS-RAF-MEK-ERK pathway. To ascertain 
the degree to which this finding exhibits clinical relevance, it would be interesting to learn 
whether CK2α is also required for resistance in a subset of treatment-resistant BRAF-mutant 
melanoma.  If so, the use of inhibitors to disrupt CK2α functions could be of clinical value. 
Although my data sheds some light on the necessity of CK2α in intrinsic resistance in cell 
culture, the effects were relatively modest, likely due to the already very high sensitivity of the 
A375 melanoma cell line to treatment with BRAF/MEK inhibitors. It is almost impossible to find a 
cell line that is both an appropriate candidate for treatment with BRAF inhibitors and also 
intrinsically resistant to BRAF inhibition.  This is owing to the points that only BRAF-mutant cells 
are sensitive to BRAF inhibitors, and that non-BRAF-mutant cells are not candidates for BRAF 
inhibition (Holderfield et al., 2014b). However, it is possible to test the involvement of CK2α in 
acquired resistance. To do this, I could generate BRAF inhibitor-resistant cell lines by exposing 
sensitive cells to increasing concentrations of inhibitor for a long period of time, and then 
determine whether sensitivity is restored upon depletion of CK2α protein expression. I could 
also determine whether CK2α protein levels are increased in resistant cells, and thereby serve 
as a biomarker for resistance. 
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Although CK2 has been reported to promote drug resistance to both conventional and 
targeted therapeutics, all the reported studies have been performed in cell lines or in animal 
models (Borgo et al., 2013; Di Maira et al., 2007; Kreutzer et al., 2010; Salizzato et al., 2016; 
Stolarczyk et al., 2012; Wang et al., 2015).  My TCGA-based data analysis revealed a 
significant increase in CSNK2A1 mRNA expression when comparing metastatic to primary 
melanoma (Figure 4.1).  However, although this increase suggests that CK2α may be involved 
in disease progression in melanoma patients, these data are not linked to patient response to 
treatment with RAF or MEK inhibitors. Unfortunately, patient inhibitor treatment data are lacking 
in TCGA samples. Therefore, no direct conclusions can be drawn on the role of CK2α in 
resistance to RAF or MEK inhibitors from these data. One approach to testing the clinical 
relevance of CK2α in resistance to RAF or MEK inhibitors at a smaller scale would be to 
perform immunohistochemical staining for CK2α on tumor tissue samples from patients not 
responding to initial therapy (intrinsic resistance), and from patients who have progressed after 
treatment (acquired resistance), and comparing them both to treatment-naïve sensitive tumor 
samples. Additionally, shRNA delivery of CK2α knockdown constructs into tumors of patient-
derived xenografts would be useful in studying whether CK2α is a driver of resistance or simply 
a passenger. 
 In addition to resistance to RAF/MEK inhibitors, CK2 may also play a role in immune 
modulation. Melanoma is an immunogenic tumor that overcomes the control of the immune 
system through impairment in dendritic cell maturation, loss of dendritic cells (Failli et al., 2013), 
and excess production of tolerogenic cytokines and growth factors in the microenvironment 
(Umansky and Sevko, 2012), which is known as tumor-induced immunosuppression. This led to 
decades of research into the development of antibodies that elicit effective anti-tumor responses 
through sustained activation of the immune system. Accordingly, immune checkpoint inhibitors 
(ipilimumab, pembrolizumab, and nivolumab) have been approved by the FDA for the treatment 
of advanced melanoma. However, CD4+ regulatory T cells (Treg cells), which are essential for 
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peripheral tolerance, have been shown to possess high CK2 activity (Ulges et al., 2015). The 
authors found that Treg cell–specific deficiency in CK2β resulted in the spontaneous 
development of excessive T helper type 2 (TH2) responses in the lungs (Ulges et al., 2015). 
Therefore, I posit that CK2 hyperactivity leads to increased immune suppression. If so, CK2 
overexpression/hyperactivity may reduce the effectiveness of immunotherapies in the clinic. I 
postulate that CK2 levels may also modulate the new treatment regimens combining RAF-MEK 
inhibitors with checkpoint modulators that are now being tested in melanoma patients 
(www.clinicaltrials.gov). 
 
How does kinase-inactive CK2α promote resistance to inhibitors of RAF or MEK? 
My study unexpectedly showed that a kinase-inactive mutant of CK2α (K68M) promotes 
resistance to BRAF or MEK inhibition, similar to wild-type CK2α. In Chapter 3, I provided a 
possible explanation: that wild-type and kinase-inactive CK2α bind equally well to the RAF-
MEK-ERK pathway scaffold Kinase Suppressor of Ras 1 (KSR1).  I hypothesized that the 
kinase function of CK2α is not critical to the scaffolding efficiency of KSR, and that kinase-
deficient CK2α binds to KSR1 and promotes scaffolding as efficiently as wild-type CK2α, 
therefore ensuring maximal signal transduction efficiency. To test this hypothesis, I would first 
need to identify the region of CK2α that binds to KSR1, then mutate it to generate a KSR 
binding-deficient CK2α. Using this construct, I could then ask whether the resistance profiles 
associated with wild-type and/or kinase-inactive CK2α are dependent on their binding to KSR1. 
An alternative possibility is grounded in the intricate interaction between CK2 subunits. 
As mentioned earlier, protein kinase CK2 is a heterotetrameric enzyme that is comprised of two 
regulatory subunits (beta), and two catalytic subunits (alpha or alpha’). Mounting evidence 
suggests CK2α can exist free of CK2β, and vice versa, raising the possibility that the regulation 
and function of monomeric CK2 subunits may be distinct from those of the tetramer (Guerra et 
al., 1999; Heller-Harrison and Czech, 1991; Lebrin et al., 1999; Martel et al., 2001; Theis-Febvre 
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et al., 2005). In most cases, the catalytic activity of the holoenzyme is somewhat higher than the 
isolated subunits, but exceptions exist. For example, calmodulin is only phosphorylated by the 
catalytic subunits but not the holoenzyme (Pinna, 2002). It is interesting to speculate that 
resistance caused by CK2α overexpression is dependent only on “free” CK2α and not on CK2α 
in the form of the holoenzyme. In this hypothetical model, kinase-inactive CK2α(K68M) 
competes with CK2α(WT) for CK2β binding, thereby releasing CK2α(WT) monomers. In this 
scenario, with the kinase function important in regulating resistance, one could enhance 
sensitivity by using a CK2α inhibitor, such as CX-4945 (Siddiqui-Jain et al., 2010). Indeed, I 
have preliminary data suggesting that this could be true (Figure 4.2). In my preliminary 
experiment, a fixed concentration (15 µM) of CX-4945 enhanced the sensitivity of CK2α-
expressing A375 cells to vemurafenib, reducing the GI50 from 0.79 µM to 0.12 µM. 
However, two premises must be fulfilled to support this bold speculation. First, given the 
expression levels of ectopic CK2α(K68M) versus endogenous CK2α(WT) (~10-fold), the 
endogenous molarity of tetrameric CK2 needs to reach at least approximately 10-times the 
molarity of monomeric CK2α. There is scarce evidence in the current literature on the relative 
abundance of CK2 subunits in cells or on the equilibrium between tetrameric and monomeric 
CK2. Even if available, this ratio can be highly context-specific, changing with tissue, disease 
state, etc. (Ferrer-Font et al., 2015; Stalter et al., 1994). Therefore, at present it is difficult to 
extrapolate any published values to those in my cell lines. Second, the dissociation constant (Kd) 
of CK2α(K68M) binding to CK2β needs to be smaller than that of CK2α(WT). Goldberg and 
colleagues were able to demonstrate with CK2α(K68A) that this kinase-inactive mutant has the 
capacity to integrate the endogenous CK2 subunit pool both as an isolated kinase-inactive 
alpha subunit and when associated with the beta subunit in a kinase-inactive tetramer, implying 
that the Kds of wild-type and K68-mutated CK2α may be comparable (Lebrin et al., 2001). 
Another kinase-inactive variant of CK2α, i.e., CK2α A156, is known to bind tightly to CK2β, 
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efficiently compete with wild-type CK2α, and act as a dominant-negative (Cosmelli et al., 1997; 
Korn et al., 2001). One way to test my model would be to titrate in increasing amounts of the 
CK2β regulatory subunit, while overexpressing a fixed amount of CK2α. If sensitivity of cells to 
RAF/MEK inhibition gradually increases in parallel with CK2β expression, then that would 
support my speculation that it is the “free” pool of CK2α that is primarily responsible for 
resistance. 
 
How does CK2α regulate DUSP6 protein levels? 
An unexpected and interesting preliminary finding in the first part of my doctoral work is 
the regulation of DUSP6, an ERK-specific phosphatase, by CK2α. Specifically, overexpression 
of wild-type but not kinase-inactive CK2α dramatically decreased DUSP6 protein, which could 
be rescued by the addition of MG132, and did not correlate with DUSP6 mRNA (Figure 3.5). 
These data suggest that the kinase function of CK2α is required for regulation of DUSP6 at the 
post-translational level, possibly through phosphorylating and thus targeting DUSP6 for 
proteasomal degradation. In one study, the authors transfected equal amounts of MKP3 
(DUSP6) and increasing amounts of CK2α into COS-7 cells, and observed a slight increase in 
ERK phosphorylation (Castelli et al., 2004). However, they failed to note the reduction in 
MKP3/DUSP6 protein, but instead concluded that the increase in ERK phosphorylation was due 
to reduced MKP3/DUSP6 phosphatase activity. They did show that CK2α phosphorylates 
MKP3/DUSP6 in vitro, but did not test whether this phosphorylation occurs in cells or affects 
MKP3/DUSP6 phosphatase activity on ERK. Further experiments will be needed to identify the 
specific phosphorylation sites and the effect(s) of phosphorylation on DUSP6. 
It would also be worthwhile to investigate the contribution of CK2β to DUSP6 regulation, 
since, as mentioned above, the CK2 holoenzyme and the catalytic subunits can exert different 
effects on substrates (Pinna, 2002). My preliminary data show that, while CK2α expression 
diminished DUSP6 protein, CK2β dramatically increased it. Concurrent expression of both alpha 
 96 
and beta subunits resulted in a compromised expression of DUSP6 (Figure 4.3). These results 
indicate that CK2α and CK2β or the holoenzyme play opposing roles in DUSP6 regulation. 
Although CK2β is regarded only as a regulatory subunit, it is endowed with independent 
physiological and pathophysiological roles (Filhol et al., 2015; Huillard et al., 2010; Lee et al., 
2009; Lin et al., 2010; Pallares et al., 2009; Yde et al., 2008). Curiously, direct sequence 
analysis of CK2β did not show any significant similarity of this protein to other proteins in the 
databank with the exception of the stellate protein from Drosophila (Bozzetti et al., 1995). 
However, other methods of analysis may be more appropriate.  For example, PropSearch is a 
program that is not based on direct sequence comparison but rather on the aggregate analysis 
of many properties and characteristics of proteins such as size, amino acid composition, 
isoelectric points and frequency of amino acid pairs (Hobohm and Sander, 1995).  PropSearch 
revealed a high level of similarity between the CK2β subunits and some protein phosphatases, 
including protein phosphatase 2A, and ion transport ATPases (Korn et al., 1999). Future 
experiments using more physiologically relevant systems that enable fine-tuning of subunit 
expression to dissect the functions of CK2α, CK2α', CK2β, and the CK2 holoenzyme will 
provide further insight into the regulation of the kinase activity of CK2 and the sophisticated 
interplay among its subunits. 
 
Why is KRASWT more critical to cell survival than oncogenic NRAS in NRAS-mutant 
melanoma? 
 
In the second part of my thesis work, I revealed that NRAS-mutant melanoma cells are 
dependent on KRASWT for cell survival, proliferation, and various aspects of the transformed 
phenotype. Since NRAS is the oncogenic RAS isoform in this tumor type, one might assume 
that depleting cells of NRAS would lead to a stronger effect in all phenotypes, as was reported 
for an NRAS-mutant rhabdomyosarcoma cell line (Young et al., 2013). However, my data 
suggest otherwise. As shown in Figure 4.4, the more rapidly proliferating (high fold-changes in 
 97 
absorbance over time) NRAS-mutant cells SK-MEL-147 and Sbc12 did not appear to distinguish 
among the RAS isoforms with respect to their requirements for proliferation.  In contrast, the 
more slowly proliferating lines SK-MEL-119 and Mel224 (low fold-changes in absorbance over 
time) tended to respond more strongly to KRASWT knockdown than to NRASmut knockdown 
during the first 5-6 days, the time frame used by other studies (Grabocka et al., 2014; Young et 
al., 2013). This observation implies that cells may tolerate more cell divisions upon NRAS 
depletion than upon KRAS depletion. In addition, when monitoring cells in culture upon RAS 
isoform knockdown, I also observed that KRAS-depleted cells undergo apoptotic cell death 
faster than others (data not shown). Accordingly, 2 days post viral transduction, PUMA was 
selectively induced at the mRNA level in KRAS-depleted cells (Figure 3.8). Of note, although 
both NRAS and HRAS were compensating for the loss of KRAS by upregulating their own 
mRNA and/or protein expression (Figure 3.1), they were incapable of attenuating cell death. 
These findings all point to a critical role of KRAS in maintaining fundamental cellular functions 
such as survival. 
Nevertheless, technical issues may confound these observations. It is possible that 
KRAS knockdown is more efficient than NRAS knockdown in these cells. However, such a 
conclusion cannot be drawn based solely on western blots or qPCR, due to differences in 
antibody and primer efficiencies. To better address this question, I could use CRISPR-Cas9-
mediated knockout to eliminate the desired RAS isoform. This method, however, is further 
complicated by the necessity of selecting clones in which the gene of interest has been 
successfully knocked out.  This not only gives rise to cells that have fully reprogrammed to 
accommodate loss of a given RAS isoform, but also creates an additional variable, that of clonal 
variation.  
In addition, genetic depletion of oncogenic NRAS may also target any wild-type NRAS 
copies in the cells, which could affect the consequences of depletion of mutant RAS either 
negatively or positively. For example, HRASWT and KRASWT act as tumor suppressors in 
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experimental models of HRAS-driven non-melanoma skin cancer and KRAS-driven lung cancer, 
respectively (To et al., 2013). If NRASWT also acts as a tumor suppressor in the context of 
NRAS-mutant melanoma, then depleting it may partially rescue loss of oncogenic NRAS. This 
could help to explain why knockdown of NRAS in these NRAS-mutant melanoma lines did not 
impair their growth and survival to the same extent as knockdown of KRASWT. 
 
What are the functional consequences of the suppression of rpS6 phosphorylation that 
is induced upon KRAS silencing? 
 
Using an unbiased reverse phase protein array (RPPA) approach, we identified an 
unexpected link between KRAS and the phosphorylation state of ribosomal protein S6 (rpS6). 
Compared to silencing of either NRAS or HRAS, depletion of KRAS resulted in the strongest 
suppression of rpS6 phosphorylation at Ser235 and Ser236 (Figure 3.4A,B). rpS6 is one of the 
33 proteins that constitute the 40S small subunit of eukaryotic ribosomes. It was the first, and for 
many years the only subunit that has been shown to undergo inducible phosphorylation 
(Meyuhas, 2015). As part of the translation machinery, rpS6 and its phosphorylation have been 
thought to be primarily involved in protein synthesis. However, several studies demonstrated an 
apparent lack of a role for rpS6 phosphorylation in protein synthesis (Garelick et al., 2013; 
Johnson and Warner, 1987; Ruvinsky et al., 2005). Similarly, genetic studies deleting its 
upstream kinases, S6K1 and S6K2 (Chauvin et al., 2014; Mieulet et al., 2007), also reported no 
effect on global protein synthesis. Although not significantly involved in global protein synthesis, 
rpS6 phosphorylation has been reported to promote cap-dependent translation, polysome 
assembly (Roux et al., 2007), and ribosomal genesis (Chauvin et al., 2014). Other physiological 
roles of rpS6 phosphorylation include cell size regulation, normal muscle function, hypertrophic 
responses, cell proliferation, clearance of apoptotic cells, tumorigenicity (Meyuhas, 2015), and 
metabolic signaling in CD8 T cells (Salmond et al., 2009). To examine whether impaired rpS6 
phosphorylation contributes to the defects that I observed in cell proliferation and cell cycle 
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progression of NRAS-mutant melanomas in which KRAS had been knocked down (Volarevic et 
al., 2000), I could generate a series of phosphorylation-mimetic or -deficient mutants of rpS6, 
and compare their abilities to rescue cell proliferation and/or cell cycle arrest to those of wild-
type rpS6. There is, however, a caveat to this method: ectopic expression of those constructs 
may disrupt the endogenous stoichiometry, and lead to unwanted effects that may complicate 
interpretation of data. Therefore, it will be critical to express these constructs at levels similar to 
the endogenous proteins.  Additional experiments along the same lines but elucidating other 
functional outcomes of rpS6 hypophosphorylation induced by knockdown of KRAS will advance 
our understanding of the currently elusive roles of such modifications. 
 
How do RAS isoforms differentially engage effector signaling? 
My results suggest that RAS isoforms differ in their ability to engage downstream 
effector signaling  (Figure 3.2). Their differential regulation of AKT and ERK phosphorylation 
was even more prominent at later time points (Figure 4.5). In fact, differences among RAS 
isoforms in signaling to the canonical effector pathways RAF-MEK-ERK and PI3K-AKT-mTOR 
have been reported (Newlaczyl et al., 2014; Omerovic et al., 2007; Voice et al., 1999; Yan et al., 
1998), but these results are contradicted by other studies that did not show specific coupling to 
these major pathways (Omerovic et al., 2008). In COS cells, compared to HRASG12V, KRASG12V 
more efficiently recruited RAF-1 to the plasma membrane, and was also a more potent activator 
of membrane-recruited RAF-1. In contrast, HRASG12V was more potent in activating PI3K than 
KRASG12V (Yan et al., 1998). A more thorough study compared the relative ability of oncogenic 
forms (G12V) of all four RAS homologs (HRAS, NRAS, KRAS4A, and KRAS4B), to activate 
Raf-1, induce foci formation, enable anchorage-independent growth, and stimulate cell 
migration in COS-1 cells, NIH 3T3 mouse fibroblasts, Rat-1 fibroblasts, and RIE-1 rat intestinal 
epithelial cells (Voice et al., 1999).   The RAS isoforms displayed very different potentials to 
promote each phenotype. For Raf-1 activation, KRAS4B > KRAS4A >>> NRAS > HRAS; for 
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focus formation, HRAS ≥ KRAS4A >>> NRAS = KRAS4B; for anchorage-independent growth, 
KRAS4A ≥ NRAS >>> KRAS4B = HRAS = no growth; and for cell migration, KRAS4B >>> 
HRAS > NRAS = KRAS4A = no migration. Walsh and Bar-Sagi compared the abilities of 
HRASG12V and KRAS4BG12V to activate the Tiam1-Rac-PAK pathway in REF-52 rat fibroblasts, 
using three Rac-dependent readouts: induction of membrane ruffling and pinocytosis, 
stimulation of cell motility, and PAK binding. In all assays, KRAS4BG12V displayed superior ability 
to stimulate the pathway than did HRASG12V (Walsh and Bar-Sagi, 2001). A comprehensive 
analysis of mutant RAS isoforms HRASG12V, NRASG12D, and KRASG12V to regulate gene 
expression in preneoplastic rat 208F cells revealed 26 genes whose expression was regulated 
in a RAS isoform-specific manner (Zuber et al., 2000). Therefore, in my system, future 
experiments will need to address the following questions: Do RAS isoforms differentially impact 
Tiam1-Rac-PAK signaling, as I might expect, given that the morphological features that I 
observed (Figure 3.2) were unique to knockdown of each isoform? How effective are RAS 
isoforms in transmitting signals through RAF-MEK-ERK or PI3K-AKT-mTOR pathways? Why do 
mutant NRAS and wild-type KRAS regulate ERK signaling in opposite directions? etc. 
Another issue worth highlighting is that "KRAS" is a simplified representation of two very 
distinct isoforms, KRAS4A and KRAS4B. As shown in Figure 1.2, KRAS4A possesses a very 
different hypervariable region than does KRAS4B. In addition to the CAAX motif for 
farnesylation, KRAS4B contains a stretch of polybasic residues that promotes electrostatic 
interactions with the negatively charged membrane phospholipids, whereas KRAS4A has both a 
bipartite polybasic region as well as a palmitoylatable cysteine. KRAS4A was, and sometimes 
still is, the ignored KRAS isoform, for various reasons, mainly because it was shown to be much 
less important than KRAS4B in during mouse embryonic development (Plowman et al., 2003), 
and also due to the proposedly lower expression of this variant (Capon et al., 1983; Pells et al., 
1997; Plowman et al., 2006). However, a recent study in human colorectal cells revealed that 
both mRNA and protein levels of KRAS4A and KRAS4B are relatively similar (Tsai et al., 2015), 
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calling for a new view of RAS isoforms (Nussinov et al., 2016). Remarkably, KRAS4A was found 
to be active at the plasma membrane even in the absence of the palmitoyl lipid (Tsai et al., 
2015), suggesting that KRAS4A may exist in two distinct states. In state1, KRAS4A is only 
farnesylated, resembling KRAS4B; in state 2, KRAS4A is both farnesylated and palmitoylated, 
like NRAS. My knockdowns of KRAS in NRAS-mutant melanoma cells depleted both splice 
variants.  Future studies could determine whether loss of either KRAS splice variant alone 
would have similar consequences as loss of both. 
 
How does KRAS control rpS6 phosphorylation? 
I observed that, whereas neither the MEK inhibitor trametinib nor the ERK inhibitor 
SCH7782984 significantly impacted rpS6 phosphorylation in cells with a non-targeting control 
knockdown construct, either inhibitor abolished the residual phosphorylation of rpS6 remaining 
after KRAS knockdown (Figure 4.5).  This result suggests that the MEK-ERK pathway is not 
primarily responsible for S235/S236 phosphorylation in this system, and that KRAS mainly 
utilizes another kinase, notably S6K1 (Figure 3.4C), to control rpS6 activity. 
Contrary to the widely-held perception that rpS6 phosphorylation serves as a reliable 
readout of mTOR pathway activity (Andreoli et al., 2015; Iwenofu et al., 2008), I showed that 
rpS6 phosphorylation is suppressed upon KRAS depletion in NRAS-mutant melanoma cells 
regardless of AKT or mTOR activity (Figure 3.2B). One obvious explanation is that KRAS 
signals to other intermediates to regulate S6K1 activity. Aside from phosphorylation by 
mTORC1 at Thr389 (Jacinto et al., 2004; Kim et al., 2003), S6K1 is also directly phosphorylated 
by PDK1 at Thr229 (Alessi et al., 1998; Pullen et al., 1998). While Thr389 phosphorylation is 
required for phosphorylation at Thr229, the ability of the latter to induce S6K activation is in turn 
controlled by phosphorylation of Thr389 (Alessi et al., 1998). Therefore, it is possible that KRAS 
reglates the ability of PDK1 to phosphorylate S6K1, which can be partially tested by examining 
the level of PDK1 phosphorylation on Ser241 upon KRAS depletion, whose autophosphorylation 
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is necessary for PDK1 activity (Casamayor et al., 1999). Further, I can measure the effects of 
mTORC1 or PDK1 inhibition on rpS6 phosphorylation at S235/236 by using rapamycin and a 
PDK1 inhibitor (e.g., GSK2334470 (Najafov et al., 2011)), respectively, and determine their 
relative contributions. An alternative hypothesis is that KRAS depletion induces PP1, the only 
known phosphatase of rpS6 (Belandia et al., 1994; Hutchinson et al., 2011), enhancing 
dephosphorylation of rpS6. To this end, I could assess whether Calyculin A, a potent inhibitor of 
PP1, rescues the rpS6 hypophosphorylation that is a result of KRAS knockdown. Other 
regulators of rpS6 phosphorylation at S235/236 include protein kinase A (PKA) (Biever et al., 
2015; Chowdhury and Kohler, 2015; Moore et al., 2009), and less commonly, protein kinase C 
(PKC) (House et al., 1987) and Death-Associated Protein Kinase (DAPK) (Schumacher et al., 
2006). The involvement of PKA can be tested with forskolin, a stimulator of cyclic AMP (cAMP) 
and hence PKA. 
In summary, the specific pathway or pathways by which KRAS selectively controls rpS6 
phosphorylation is currently unknown. Future studies unraveling the detailed mechanisms will 
be an important step towards delineating a RAS isoform-specific engagement of downstream 
signaling. 
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Figure 4.1. CK2α (CSNK2A1) mRNA expression is associated with melanoma 
progression.  
CK2α (CSNK2A1) mRNA expression in primary and metastatic melanomas was analyzed 
based on data from The Cancer Genome Atlas (Cancer Genome Atlas, 2015). p-values were 
calculated by Student's t-test. 
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Figure 4.2 CK2α inhibition sensitizes CK2α-overexpressing A375 cells to BRAF inhibition 
by vemurafenib. 
A375 melanoma cells stably overexpressing CK2α (A375-CK2α) were treated with a fixed-dose 
of CX-4945 (15 µM) plus varying concentrations of vemurafenib. A dose-response curve was 
generated by MTT staining on day 3, and GI50 values were calculated with Prism 6 (GraphPad). 
GI50(vemurafenib) = 0.7902 µM; GI50(vemurafenib + CX-4945) = 0.1251 µM. 
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Figure 4.3. Opposing effects of CK2α and CK2β on DUSP6 protein expression. 
To determine the effects of CK2 subunits on DUSP6, A375 cells were virally transduced with 
HA-GFP (control), FLAG-CK2α, HA-CK2β, or FLAG-CK2α + HA-CK2β. Two days post infection, 
cells were harvested, and blotted for DUSP6 expression. 
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Figure 4.4. Proliferation of rapidly dividing and slowly dividing NRAS-mutant melanoma 
cells depends differentially on NRAS and KRAS. 
MTT proliferation curves for a panel of NRAS-mutant melanoma cells (SK-MEL-147, Sbc12, SK-
MEL-119, and SK-MEL-103) upon NRAS or KRAS depletion. 
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Figure 4.5. AKT and ERK phosphorylation is differentially regulated by RAS isoforms. 
shRNA depletion of NRAS, KRAS or HRAS was performed in SK-MEL-147 cells, and proteins 
were harvested on day 3 and day 4 post infection. Expression of both total and phosphorylated 
forms of AKT and ERK was examined by western blotting. 
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Figure 4.6. ERK pathway signaling controls residual rpS6 phosphorylation after KRAS 
depletion. SK-MEL-147 cells were treated with MEK inhibitor trametinib (2 nM, left) or ERK 
inhibitor SCH772984 (1 µM, right) for 1 hour in the presence or absence of KRAS, and lysates 
were probed for rpS6 phosphorylation at Ser235/236. 
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